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Confounding is a critical concern in non-experimental comparative effectiveness 
research. Although regression can reduce confounding, issues of non-positivity and model 
dependence remain when baseline characteristics between treatment groups vary 
considerably. As such, we evaluated the ability of matching techniques to balance baseline 
characteristics between treatment groups using non-experimental data. We identified a set of 
balance diagnostics that assessed key differences in baseline covariates with potential for 
confounding. These diagnostics were used in a novel systematic approach to developing and 
evaluating models for use in propensity score matching that optimized balance and data 
retention. We then compared the performance of propensity score and coarsened exact 
matching strategies in optimizing balance and data retention, using non-experimental data 
from a pan-Canadian prostate cancer database. Both matching techniques balanced baseline 
covariates adequately and retained approximately 70% of the data. Improvements in balance 
after matching were associated with closer agreement in the effect estimate with the 
associated RCT compared to regression modeling alone. Furthermore, regression modelling 
after matching led to even closer agreement compared to matching alone. To study the role of 
treatment selection and prostate cancer outcomes, we performed a systematic review and 
meta-analysis that examined the rate of prostate cancer-specific mortality among those with 
high-risk non-metastatic prostate cancer who were initially treated with radiation or surgery. 
No statistically significant difference was found between groups in this analysis; however, this 
might be explained by the moderator variables of radiation type. In follow-up to this analysis, 
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we compared the rate of metastatic progression following treatment between those with 
unfavorable-risk non-metastatic prostate cancer and treated with radiation or surgery, using 
data acquired from two Ontario cancer centers. The novel approaches to matching developed 
in this thesis were used to balance baseline characteristics between groups. Results from this 
comparison showed no statistically significant difference between treatment groups. In 
summary, a systematic approach to matching can be effective in balancing baseline covariates 
and producing more accurate effect estimates from non-experimental data. Moreover, initial 
treatment selection between radiation and surgery in the realm of higher risk prostate cancer 
does not appear to significantly influence important oncological outcomes.  
Keywords: Comparative effectiveness research; non-experimental data; confounding; balance; 
propensity score matching; coarsened exact matching; regression analysis; prostate cancer; 
unfavorable-risk non-metastatic; high-risk non-metastatic; radiation therapy; external beam 




Summary for Lay Audience 
 
Accounting for bias in research performed using nonrandomized data is necessary to 
validly quantify differences in treatment effectiveness. Although statistical techniques can 
reduce bias, they are of limited value when treatment groups vary substantially. Matching 
individuals between treatment groups can overcome this issue; however, depending on how 
matching is accomplished, different issues may persist. For example, matching directly on all 
patient characteristics can lead to too few matches from which to draw valid conclusions. 
Alternatively, using a simple score derived from patient characteristics (e.g., a health score as 
defined by the presence of multiple illnesses, health behaviors such as smoking, exercise and 
diet, and age) might be limited in its ability to differentiate between those with similar scores 
who might still vary considerably in important ways. As such, we compared the ability of 
different matching strategies to balance important patient characteristics between treatment 
groups, while generating enough matches. To accomplish this, a set of tests were identified 
from previous research that adequately quantify important differences between treatment 
groups when attempting to estimate treatment effects. We developed a systematic approach 
to matching that optimized similarity in characteristics between groups, while maximizing the 
number of matches made. Finally, the ability of two different matching strategies were 
compared using nonrandomized data obtained from a pan-Canadian radiotherapy database of 
men diagnosed with prostate cancer. Both strategies performed well, leading to minimal 
differences between treatment groups, while generating enough matches to validly estimate 
treatment effects. In follow-up to the matching project using prostate cancer data, we 
 viii 
aggregated effect estimates from studies comparing the effectiveness of radiation and surgery 
in treating high-risk prostate cancer, using a research technique called a systematic review and 
meta-analysis. No difference was found in the effectiveness of these two treatment modalities 
in this patient population. The last project in this thesis used the matching strategies developed 
in earlier chapters to compare the effectiveness of radiation and surgery in the treatment of 
higher-risk prostate cancer with newly acquired patient data. Like other studies, no difference 
in effectiveness was identified between these treatment modalities. However, due to data 
limitations, these estimates could not account for several potential biases which are explored in 
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Thesis Map and Orientation 
 
The goal of this thesis was to investigate methods used to mitigate bias when comparing 
the effectiveness of radiation therapy relative to radical prostatectomy as initial management 
options in treating unfavorable-risk non-metastatic prostate cancer. The first chapter provided 
a general review of the carcinogenesis, epidemiology, and clinical management of prostate 
cancer to provide understanding of the nature of this disease, information on the relative 
health burden and the standard of care in screening, diagnosis, prognosis, and management. 
This chapter also provides a review of the current state of research on the effectiveness of 
available treatments used in the management of unfavorable-risk non-metastatic prostate 
cancer and associated knowledge gaps. The challenges to performing RCTs when comparing 
radiation therapy and radical prostatectomy, which are the upfront standard of care options, 
are reviewed and illustrate the importance of evidence generated from non-experimental data 
when estimating their relative treatment effectiveness. A discussion on how confounding 
manifests when comparing the effectiveness of radiation therapy and radical prostatectomy 
using non-experimental data obtained from routine clinical practice is provided.  
In chapter two, commonly employed methods for preventing and controlling 
confounding when performing comparative effectiveness research using non-experimental data 
(e.g., regression modeling and matching strategies) are explored. To measure the effectiveness 
of matching strategies in preventing confounding, balance in the distribution of baseline 
covariates with potential for confounding needed to be assessed. As such, in chapter three, 
available balance diagnostics are reviewed and a set that comprehensively measured 
imbalances in the multivariable distribution of baseline covariates with prognostic value when 
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comparing treatments using non-experimental data was subsequently identified. The identified 
set of balance diagnostics is then used in the research work described in chapter four to inform 
a systematic approach to developing and evaluating propensity score models for matching. An 
illustration is provided using a treatment comparison from the prostate cancer literature. In 
chapter five, the performance of propensity score matching versus coarsened exact matching in 
balancing baseline covariates and thus preventing confounding is compared. This involved the 
use of a pan-Canadian radiation therapy database to provide two treatment comparisons. 
Treatment comparisons were informed by two RCTs to enable guidance in the interpretation of 
effect estimates before and after matching so that one could infer whether matching led to 
effect estimates closer to or further from those obtained from RCTs.  
In chapter six, a systematic review and meta-analysis of available non-experimental 
studies comparing the rate of prostate cancer-specific mortality between men diagnosed with 
high-risk non-metastatic prostate cancer who were initially treated with radiation therapy or 
radical prostatectomy is performed. This analysis was performed to assess the quality and to 
survey the findings available in this patient population which is lacking randomized data to 
guide treatment selection. In chapter seven, the relative rate of metastatic progression 
between men diagnosed with unfavorable-risk non-metastatic prostate cancer who initially 
underwent radiation therapy or radical prostatectomy is estimated. For this project, non-
experimental data were obtained from a Canadian academic multidisciplinary clinic where men 
eligible for both radiation therapy and radical prostatectomy were consulted by both a surgeon 
and radiation oncologist so were less likely to differ prognostically than those seen in traditional 
clinics. The matching methods developed in chapter four and five were used to mitigate 
 3 
differences in the distribution of baseline covariates and the balance diagnostics identified in 
chapter three were used to measure their effectiveness.  
This thesis concluded with an integrated discussion of the findings from the projects 
performed and provided suggestions for future research on this basis. 
  
 4 
Chapter 1: An Epidemiological and Clinical Review of Prostate Cancer 
 
1.1 Prostate Carcinogenesis and Epidemiology 
 
The prostate is an exocrine gland that makes part of the male reproductive tract.(1) It 
serves to secrete an alkaline fluid as part of the ejaculate, which protects sperm from the acidic 
vaginal environment to promote successful fertilization.(1) Prostate cancer (PCa) typically 
develops in the prostatic epithelial tissue, and growth is typically dependent on androgen 
signaling.(2) PCa was the second leading cancer diagnosis and fifth leading cause of cancer 
death globally in 2018.(3) In 2020, the Canadian Cancer Society estimated that about 23,300 
men would be diagnosed with PCa in Canada and over 4,200 of those diagnosed would die from 
their disease.(4) Age is a well-established risk factor for PCa, with incidence increasing sharply 
after 50 years of age.(5) The prevalence in Canada is approximately 100 per 100,000 men 
between 50 and 54 years of age, increasing to 700 per 100,000 among men aged 60-64 and 
over 700 per 100,000 for men older than 80 years.(6) Family history is also a risk factor for PCa, 
increasing the incidence at an earlier age in men with compared to without a family history of 
PCa.(7,8) Differences in incidence rates and severity of disease have also been noted for 
different races.(9,10) In 2015, 157.6 per 100 000 black men were diagnosed with PCa, 
compared with 93.9 per 100 000 white men in the United States.(10) Black men also tend to 
have more aggressive disease on diagnosis and are more likely to die from their PCa than white 
men.(9) 
 
1.2 Screening and Diagnosis 
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 In earlier stages of PCa, cases are generally asymptomatic.(11) In later stages of the 
disease, urinary symptoms include hesitancy, nocturia and retention.(11) In the case of 
advanced metastatic PCa, systemic signs and symptoms may arise, including fatigue, weight 
loss, and bone pain.(11) Most cases of PCa are identified in their earlier stages through 
prostate-specific antigen (PSA) testing.(12)  
The PSA is an androgen-regulated serine protease produced by the epithelial cells of the 
prostate.(13) The PSA is often elevated in the context of PCa, benign prostatic hyperplasia and 
prostatitis, and transiently after prostate biopsy, acute urinary retention, physical activity, and 
other activities.(1) PCa screening using PSA has been a controversial issue over the past few 
decades.(14) Although it increases diagnosis of indolent disease that may lead to ‘unnecessary’ 
treatment, it also increases diagnosis of aggressive PCa in its earlier and more treatable 
stages.(15) The most recent guidelines for PCa screening in Canada come from the Canadian 
Urological Association, which were published in 2017.(15) Since evidence remains equivocal 
surrounding the relative benefits and harms of PSA screening for patients, it is suggested that 
men over the age of 50 with a greater than 10-year life expectancy be engaged in a shared 
decision-making process of whether or not to undergo PSA screening.(15) Men younger than 45 
years with a first or second-degree family history of PCa should also be considered for screening 
as they are at an increased risk for clinically significant PCa. Intervals between screening tests 
should be individualized according to previous PSA levels (e.g., PSA < 1 ng/ml and 1-3 ng/ml 
should repeat in four and two years, respectively).(15) More frequent intervals or adjunctive 
testing strategies should be considered for a significantly elevated PSA (i.e. > 3 ng/ml).(15) 
Deciding when to discontinue PSA screening should involve consideration of life expectancy and 
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PSA levels. For instance, men aged 60 with a PSA < 1 ng/ml, and men who are aged over 70 
years or have a less than 10-year life expectancy should have PSA screening discontinued.(15)  
Physical examination of the prostate through digital-rectal examination allows the size 
of the prostate gland to be assessed, nodules or lumps to be detected, and a clinical tumor 
stage to be assigned.(11) The digital-rectal examination and PSA testing as screening measures 
are often carried out by a general practitioner such as a family physician.(16) Results from these 
tests together with consideration of the patient’s age, family history of PCa and race are used to 
inform whether the patient should be referred to the urologist for consideration of more 
definitive forms of diagnosis through prostate biopsy and histological examination.(16) If 
appropriate, the urologist performs a prostate biopsy and sends tissue samples to the 
pathologist. The pathologist examines the microscopic appearance of the prostate’s glandular 
architecture. It is the responsibility of the pathologist to diagnose the PCa and assign a grade or 
score based on the Gleason system.(17) A Gleason grade of 1 to 2 is assigned when the 
glandular appearance is very organized and non-dysplastic upon microscopic examination.(18) 
A Gleason grade of 3 indicates that the glandular appearance is sufficiently disorganized to 
warrant a diagnosis of PCa.(18) Further information on Gleason grading will be covered in 




Risk-stratification of PCa is defined by the association of pre-treatment variables with 
the trajectory of disease following treatment. To objectively define and validate the prognostic 
value of risk-strata, characteristics of the disease are measured before treatment and are 
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correlated with measures of disease progression following treatment.(19) Risk-stratification 
serves important purposes in research and clinical contexts.(20) First, clinical trials can 
condition/adjust estimates of treatment effect on risk strata to reduce heterogeneity, therefore 
improving statistical power to identify treatment effects. This also has the added benefit of 
improving precision and accuracy in effect estimates for specific subpopulations and allows 
advances in treatment protocols to target different levels of disease appropriately (e.g., 
multimodal treatment for more aggressive diseases vs unimodal treatment for more indolent 
disease). Clinicians can use this information to guide treatment decisions regarding selection of 
modality and the use of multimodal therapies. This ultimately reduces the variability in 
treatment decisions because of clinician bias, experience, and knowledge. Risk-stratification 
also provides a common nomenclature to define PCa characteristics, improving communication 
between clinicians and institutions. This facilitates collaboration in research and patient 
management to ultimately improve progress and patient care. 
Recommended baseline characteristics used to define risk-strata in the clinical context 
include measurements of PSA, clinical stage derived from digital-rectal exam, Grade Group, 
amount of cancer on biopsy and imaging.(21) Their use in defining risk-strata is based on their 
demonstrated predictability of important disease endpoints following treatment. The following 
paragraphs describe each factor and how they relate to clinical endpoints and thus the 
rationale for their contribution in risk-stratification. A summary table is provided outlining 
current definitions of risk-strata. 
 
1.3.1 The Prognostic Role of PSA 
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Studies investigating the association of PSA and pathological outcomes following 
surgical resection of the prostate through radical prostatectomy (RP) have demonstrated 
significant correlation between rising PSA from 4 ng/ml and important clinical and surgical 
endpoints (i.e., pathological stage, organ-confined disease, extraprostatic extension, seminal 
vesicle invasion and disease-free survival).(22,23) Similar results were found following PCa 
radiation therapy (RT) in two clinical trials where high-risk PCa patients with PSA levels greater 
than 50 ng/ml had inferior clinical and biochemical endpoints (i.e., overall survival, distant 
metastasis, and biochemical failure) compared to other high-risk PCa patients.(20) Common 
ranges of PSA that are used in risk-stratification include <10, 10.1-20, and >20 ng/ml;(21,24,25) 
however, new cut-off values are also being evaluated.(20)  
 
1.3.2 The Prognostic Role of Clinical Staging 
 
Clinical staging is accomplished through digital-rectal examination, imaging, and 
histological results from tissue biopsy. Upon digital-rectal examination, presence of prostatic 
nodules, asymmetry and/or induration elevate suspicion of PCa and can help determine the 
extent of tumour involvement.(26) Imaging modalities such as transrectal ultrasound and 
magnetic resonance imaging can also detect prostatic lesions which might represent malignant 
disease.(21) The most widely used system for clinical staging is the American Joint Committee 
on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) tumor, node and metastasis 
staging system.(27) Since the work in this thesis focuses on non-metastatic PCa, only the tumor 
(T) aspect of the AJCC/UICC staging system will be reviewed. Clinical stage T1 (cT1) is a clinically 
inapparent tumor that is neither detectable on digital-rectal exam nor imaging. 
 9 
Subcategorization of cT1a and cT1b correspond to an incidental tumor finding on transurethral 
resection of the prostate involving ≤5% and >5%, respectively, of the number of chips or 
amount of tissue resected out for clinically benign disease. Patients undergo transurethral 
resection of the prostate to relieve their obstructive urinary symptoms and function, usually 
due to benign prostatic hypertrophy.(18) cT1c corresponds to identification from needle biopsy 
secondary to an elevated PSA test without palpable disease. Clinical stage T2 (cT2) are tumors 
detectable by digital-rectal exam or imaging but that are perceived to be confined within the 
prostate. cT2a tumor involves up to one-half of one lobe, cT2b involves more than one-half of 
one lobe and cT2c involves both lobes. Clinical stage T3 indicates that the tumor has grown 
outside of the prostate and either has not spread to the seminal vesicles (T3a) or has spread to 
the seminal vesicles (T3b). Clinical stage T4 indicates that the tumor has spread to tissues next 
to the prostate other than the seminal vesicles. 
The AJCC/UICC staging system describes the anatomic extent of disease, which has value 
in treatment planning. For instance, a greater cT stage indicates a greater anatomic spread of 
the disease that might warrant delivering RT to the tissues surrounding the prostatic capsule or 
pelvic lymph node dissection through RP to evaluate whether the cancer has metastasized 
beyond adjacent tissues. Increased classification, however, is not necessarily associated with 
poorer prognosis.(28) For instance, many studies have demonstrated similar PSA recurrence 
rates post-RP between cT1c and cT2a tumors.(29–34) The lack of differentiation between cT1c 
and cT2a likely results from the low sensitivity of digital-rectal examination in assessing the 
presence and extent of PCa since it relies on the clinician’s ability to detect aspects of the tumor 
and the patient’s anatomy to facilitate examination (e.g., prostates of overweight compared to 
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normal weight patients are generally more difficult to palpate). Obek and colleagues found that 
in PCa tumors characterized by digital-rectal examination as unilateral, 69% were pathologically 
bilateral and 4% were cancer free in the lobe with a palpable abnormality.(35) Moreover, 
increasing tumor involvement laterally has not significantly correlated with biochemical failure 
independent of other established prognostic factors.(36) Finally, subcategorization of T1a and 
T1b is derived from a single study, involving 117 patients that found subdividing disease into 
transurethral resection of the prostate specimens with more or less than 5% tumor was 
associated with noticeable differences in clinical outcomes.(37) Since very few instances of PCa 
are detected through transurethral resection of the prostate, these cT1 subcategorizations have 
limited applicability. 
 
1.3.3 The Prognostic Role of Grade Group 
 
Grade Group is determined by the most and second most predominant pathological 
Gleason grade on biopsy.(21) Gleason grade is based on glandular differentiation, with well-
differentiated tumors representing lower-risk PCa that tends to grow and spread slower, thus 
indicating a better prognosis.(24,25) Although Gleason grading has been reported in a variety of 
ways, the Grade Group system has been recommended for risk-stratification to inform 
decisions regarding treatment of localized prostate cancer.(17,21) However, since the data 
analyzed in the this thesis arose from before the latest Grade Group system was adopted, the 
traditional Gleason sum will be used instead. A Grade Group of 1 corresponds to the most and 
second most predominant Gleason score on biopsy of 3 and 3, respectively. This corresponds to 
a Gleason sum of 6 (3+3). A Grade Group of 2 corresponds to a Gleason sum of 7 (3+4), while a 
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Grade Group of 3 is defined by a Gleason sum of 7 (4+3). Finally, Grade Groups of 4 and 5 
correspond to Gleason sums of 8 (3+5, 4+4, or 5+3) and 9 (4+5 or 5+4) to 10 (5+5), 
respectively.(17) The prognostic ability of the Grade Group system has been validated by 
multiple institutions on the basis of 4-year biochemical progression-free survival (BPFS) rates 
with increased clinical Grade Group values corresponding to significantly decreased rates of 
BPFS.(38)  
Other measures used in the subcategorization of low-risk PCa into very low-risk PCa 
include PSA density, percentage of biopsy cores positive for malignancy, and highest 
involvement of malignant tissue in a biopsy core.(21) PSA density is a quotient of serum PSA 
and prostate volume. Specifically, a value exceeding 0.15 ng/ml of PSA per cm3 of prostatic 
tissue increases the suspicion for clinically significant PCa.(15,39) Percentage of positive biopsy 
cores has been strongly associated with PCa death when assessed as a continuous and ordinal 
variable.(40) Moreover, the extent of core involvement on tissue biopsy has also been 
associated with important endpoints (e.g., ≤10, >10-25, >25-75 and >75% core involvement 
rates corresponded to PCa death rates of 8, 21, 38, and 56%, respectively).(40) Multiple studies 
have found that men presenting with low-risk PCa who also had a PSA density <0.15ng/ml/cm3, 
≤2 positive cores on biopsy and no core with >50% involvement had a very low probability of 






Risk-categories are intended to simplify decision making and have both research and 
clinical value.(19,21) Very low-risk PCa has a metastatic progression rate of <1% while on active 
surveillance at 15 years whereas PCa progression of men with low-risk PCa while on active 
surveillance is not as clear.(42,44,45) As a result, patients with very low-risk disease should be 
strongly recommended active surveillance whereas select patients with low-risk may be offered 
definitive therapy.(21) Further subcategorization of the traditional intermediate-risk category 
into favorable and unfavorable intermediate-risk was precipitated by significant differences in 
recommended management options in imaging, pelvic node dissection during RP, and 
advisability of androgen deprivation therapy (ADT) in conjunction with RT.(21) Finally, 
substratification of high-risk PCa into high and very high-risk does not provide much clinical 
utility, as management plans are very similar even though outcomes differ significantly.(19,21) 
As a result, these risk strata have been collapsed for clinical purposes, but retain value for 
research purposes. 
Table 1.1 Risk-stratification of non-metastatic prostate cancer 
 *AUA/ASTRO/SUO Guidelines ProCaRS Risk-Stratification NCCN 
Very low risk 
PSA <10 AND Grade Group 1 AND 
clinical stage T1-T2a AND <34% of 
biopsy cores positive AND no core 
with >50% involved, AND PSA 
density <0.15 ng/ml/cc 
Clinical stage T1–T2a AND PSA ≤6 
AND Gleason score ≤6 
Clinical stage T1c, Gleason sum 
≤6, PSA <10, <3 biopsy cores 
positive, ≤50% cancer in each 
core, and PSA density <0.15 
ng/ml/g 
Low risk 
Clinical stage T1-2a AND PSA <10 
AND Grade Group 1 AND not very-
low-risk 
Clinical stage T1–T2a AND PSA >6 to 
≤10 AND Gleason sum ≤6 
Clinical stage T1-2a, Gleason sum 





Clinical stage T2b-c AND Grade 
Group 1 (with PSA 10 to <20) OR 
Grade Group 2 (with PSA <10) 
PSA ≤10 (with T2b-c OR Gleason sum 
=7) OR PSA >10 to ≤20 (with T1-2a 
AND Gleason sum ≤6) 
Clinical stage T1–T2, PSA ≤20, and 






Grade Group 2 (with either PSA 10 
to <20 or clinical stage T2b-c) OR 
Grade Group 3 (with PSA <20) 
Gleason sum=7 and at least one of 
PSA >10 to ≤20 OR T2b-c 
High risk 
PSA ≥20 or Grade Group 4-5 OR 
clinical stage ≥T3 
Core positivity <87.5% AND 
Clinical stage T3–T4 OR (PSA >20 to 
PSA <30) OR Gleason sum 8 to 10 
Clinical stage T3–T4 or PSA >20, 
or Gleason score 8–10 
 
Very high risk 
- Clinical stage T3–T4 OR (PSA >20 to 
PSA <30) OR Gleason sum 8 to 10 
Clinical stage T3b–4 
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AND (PSA >30 OR core positivity 
>87.5%) 
*AUA = American Urological Association; ASTRO = American Society for Radiation Oncology; SUO = Society of Urologic Oncology; 
ProCaRS = Prostate Cancer Risk-Stratification; NCCN = National Comprehensive Cancer Network 
 
 
1.4 Oncological Outcomes in Prostate Cancer  
 
Assessing treatment outcomes in PCa is necessary to inform patients and clinicians of 
the relative harm to benefit ratio for different therapeutic options. Outcome measures should 
be meaningful or reliably determine meaningful outcomes in PCa such as disease-free status 
and survival. As well, they should occur frequently enough to allow comparison between 
therapies and standardized to enable valid comparisons between studies. In the context of 
localized PCa, the optimal outcome is PCa-specific survival (CSS) rather than overall survival 
(OS), as PCa is slow growing and many patients with PCa die from other causes.(46) However, 
OS is also important as treatments can directly and indirectly lead to death. Unfortunately, 
meaningful comparisons of CSS might only be feasible many years after follow-up due to the 
slow growing nature of PCa.(47,48) Surrogate markers are often used to assess short-term 
outcomes associated with CSS such as changes in PSA following therapy, and development of 
radiographic or bone scan evidence of metastasis.(46) These measures have been found to 
antedate CSS by approximately 13 and 5 years, respectively, while occurring approximately 2- 
and 10-years post-intervention, respectively.(47–49) Moreover, metastatic progression has 
been found to be the primary determinant of CSS.(47,49) As a result, studies comparing new 
therapies or prognostic markers in the realm of localized PCa use such definitions to accomplish 
their work in a more reasonable time frame. 
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1.4.1 Biochemical Failure 
 
 In the context of localized PCa, values indicating biochemical failure depend on the type 
of intervention. In the setting of RP, surgeons attempt to remove all benign and malignant 
prostatic tissue, so PSA should fall to an undetectable level if treatment is successful.(50) 
However, this does not occur for about 4 weeks since serum PSA half-life is about 2.6 days.(50) 
As such, it is recommended that the first PSA-test be performed 3-months after surgery.(51) 
Approximately, 20-40% of cases will demonstrate rises in PSA level post-intervention.(52,53) 
Minimal rises in PSA may indicate incomplete resection of benign prostate tissue whereas more 
significant and rising PSA levels raise concern of persistent local or distant metastatic 
disease.(54) Although a consensus has not been reached on what denotes a significant PSA 
level post-RP, different thresholds have been proposed for indicating biochemical recurrence 
following RP, ranging from ≥0.2 to ≥0.5 ng/ml.(46) Patients with a PSA of ≥0.2 ng/ml post-RP 
are said to have biochemical failure and are 53% likely to develop clinical recurrence over 
time.(47) Others have suggested ≥0.4 ng/ml as a more clinically relevant cut-off since it has 
been shown to optimally discriminate men who later present with metastatic progression as 
well as strongly correlate with continued PSA progression, secondary therapy, and a rapid PSA 
doubling time compared to competing definitions.(49,55,56) As such, they suggest that this 
should be the standard definition of biochemical recurrence for reporting outcomes following 
RP for biochemical endpoints in clinical trials using combined modality treatment strategies and 
to identify patients suitable for systemic therapy in clinical trials post-RP.(49) However, other 
factors should be considered when deciding to initiate salvage treatment such as life-
expectancy as determined by age and general health status as well as Gleason score, 
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pathological stage, surgical margin, and lymph-node status, since these also predict biochemical 
and clinical progression, and disease-specific and overall mortality.(57)  
 Changes in PSA following RT differ compared to RP and even among different RT 
approaches, making classification of biochemical failure complicated.(58,59) As prostatic tissue 
is irradiated, cells are damaged and become inflamed, releasing PSA into the circulation.(58) A 
phenomenon known as PSA bounce also commonly occurs in the setting of radioactive seed 
implantation followed by external beam radiation (EBRT).(59) In 1996, the American Society for 
Therapeutic Radiology and Oncology initially defined biochemical failure after EBRT as three 
consecutive PSA rises after nadir.(60) The date of failure was defined as the halfway point 
between the nadir date and the first rise. This definition posed several short-comings, including 
not being linked to clinical progression or survival, performing poorly among those receiving 
ADT, biasing estimates of event-free survival and violated the proportional hazards assumption 
leading to statistical limitations in its reporting.(61) As such, the definition has been revised to 
address these shortcomings in a second consensus panel by the American Society for 
Therapeutic Radiation Oncology - Radiation Therapy Oncology Group.(61) They recommended 
that a rise of PSA by ≥2 ng/ml above the nadir should be the standard definition of biochemical 
failure after EBRT with or without ADT, which is now convention.(61) Thompson et al further 
evaluated this definition in the context of brachytherapy (BT) and found that 44% of patients 
whose PSA rose ≥2 ng/ml above nadir, subsequently fell to ≤0.5 ng/ml without intervention.(62) 
They defined this as the benign phenomenon known as PSA bounce. Other definitions of PSA 
bounce include specified increases in PSA above nadir by 0.1,(63,64) 0.2,(64–66) 15%,(67) and 
35%.(64) Interestingly, patients who experience PSA bounce after BT tend to have better 
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outcomes in terms of biochemical failure, metastatic progression, and OS than those not 
demonstrating PSA bounce.(68)  
 
1.5 Management  
 
The most established management methods include active surveillance, RT, and RP, 
while more investigative novel ablative techniques include high-intensity focused ultrasound 
and cryotherapy.(21) Many factors are involved when deciding upon treatment for PCa such as 
risk-strata of PCa, age, life expectancy, pre-treatment general function and genitourinary 
symptoms, expected post-treatment function, and potential for salvage therapy.(21) Many 
treatments are clinically acceptable in the realm of PCa with the ratio of harm to benefit often 
being equivalent.(69,70) As such, guidelines developed by the American Urological Association, 
American Society for Therapeutic Radiation Oncology and Society of Urologic Oncology stress 
the importance of a shared decision-making process that incorporates best evidence with 
patient values to determine the appropriate course of therapy.(21) This involves consideration 
of the aforementioned factors that influence treatment decision and consultation with different 
PCa care specialists.(12,21)  
 
1.5.1 Favourable-Risk Prostate Cancer 
 
The standard of care for a diagnosis of very low-risk or low-risk PCa is active 
surveillance.(71) Active surveillance entails delayed treatment in the presence of continuous 
monitoring of PCa growth and progression wherein reclassification to a higher risk of disease 
progression prompts consideration of definitive intervention.(18) This differs from watchful 
waiting wherein the consideration of treatment does not occur until symptoms and/or signs 
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emerge.(18) Watchful waiting might be the appropriate choice for an individual who has 
competing illnesses such as cardiovascular and respiratory diseases that decrease their life-
expectancy, reducing the utility of active treatment to improve life-expectancy or quality of life. 
Several longitudinal studies have indicated that delayed intervention in the context of active 
surveillance compared to immediate definitive therapy does not lead to significant differences 
in biochemical recurrence rates, positive surgical margins, extraprostatic extension,(72–74) or 
risk of incurable disease.(75,76) Moreover, multiple active surveillance programs have 
demonstrated OS rates to be between 97% to 100% at 15-years.(42,77–82) 
Based on the international success of many active surveillance programs, a best practice 
guideline was created outlining appropriate steps in active surveillance monitoring.(71) 
Guidelines suggest that following a diagnosis of very low- and low-risk PCa, patients should 
receive a PSA test every 3 to 6 months, an annual digital-rectal examination, and a 12 to 14 core 
confirmatory transrectal ultrasound biopsy within 6 to 12 months of diagnosis with biopsies 
repeated every 3 to 5 years thereafter.(71) Clinicians may also consider multiparametric MRI if 
pathologic and clinical findings are discordant,(71) as research has shown high negative 
predictive values between 83% and 100%,(83) and has shown multiparametric MRI to be a 
good predictor of disease reclassification in the context of active surveillance.(84,85)  
Upon re-biopsy, an increase in Gleason sum or volume should prompt consideration of 
definitive therapy.(86,87) Specifically, a Gleason sum of at least 7 (3 + 4) with greater than 10% 
involvement of Gleason 4 warrants definitive treatment.(71) Moreover, significant increases in 
Gleason sum 6 volume should also prompt consideration of definitive therapy; however, clear 
criteria for total volume are currently not available. These recommendations are supported by 
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results showing reduced risk of distant metastasis and PCa-specific mortality for men 
undergoing RP versus watchful waiting in the Scandinavian Prostate Cancer Group-4 
Randomized Trial.(87) The following modes of definitive treatment can be considered in the 
context of reclassification while on active surveillance. 
 
1.5.2 Intermediate-Risk Prostate cancer 
 
 As mentioned previously, intermediate-risk PCa can be categorized as favourable or 
unfavourable. Patients diagnosed with favourable intermediate-risk PCa should consider active 
surveillance.(71) The standard therapy for unfavourable intermediate-risk PCa is either RP or RT 
with adjuvant ADT.(21) Other options include RT alone, whole gland cryosurgery, high intensity 
focused ultrasound and focal therapy; however, evidence surrounding these options is less 
robust.(21) Unfavourable intermediate-risk PCa patients may also be offered active surveillance 
if life expectancy is ≤ 5 years.(21)  
 RP involves surgical removal of the prostate gland with curative intent of PCa. 
Derivations of the procedure exist, including open, laparoscopic, and robotic approaches. In the 
Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4), men randomized to RP with a 
diagnosis of Gleason sum of ≥ 7 and PSA ≥10 ng/ml had a reduced relative risk of death from 
any cause and PCa-specific mortality compared to men randomized to watchful waiting.(87) 
However, watchful waiting in this study did not emulate active surveillance in that men were 
not continuously monitored and were offered trans-urethral resection of the prostate (TURP) in 
the presence of obstructive voiding symptoms or ADT upon image detected metastases. 
Observations from the Prostate Cancer Intervention versus Observation Trial (PIVOT) also 
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indicated significant reduction in PCa-specific mortality among intermediate-risk PCa or with a 
baseline PSA ≥10 ng/ml who underwent RP.(86) Similarly, however, the observation arm did not 
include continuous monitoring but rather palliative and chemotherapy in the presence of 
symptomatic or metastatic progression. Ten-year results from the ProtecT trial demonstrated 
no difference in PCa-specific mortality among patients with localized PCa who were randomized 
to active surveillance, RP or RT+ADT.(88,89) These results did not vary according to PSA level (< 
or ≥6 ng/ml), Gleason sum (6 or ≥7), or clinical stage (T1c or T2) at diagnosis. However, 
incidence of metastatic disease and clinical progression were significantly higher in the active 
surveillance compared to the RP and RT groups. Since PCa is more often a slow growing tumor, 
the authors note that longer follow-up is necessary to ascertain results regarding CSS. 
 The practice of RT has evolved over the past few decades and encompass a number of 
techniques including EBRT, and BT.(90) EBRT approaches include intensity modulated and 
stereotactic body RT, while BT includes both low and high dose rate.(90) Low dose rate BT is 
reserved for less aggressive PCa as a monotherapy wherein radioactive seeds are placed in the 
prostate and left permanently.(18) High dose rate BT, on the other hand, involves the insertion 
of thin metal rods to direct high doses of radioactive rays to the prostate.(18) It can be used in 
conjunction with EBRT to deliver the total required RT dose in fewer treatments.(18)  
The RTOG 9408 randomized trial found benefit in RT with compared to without short-
term ADT in 10-year OS and CSS among 1979 men diagnosed with early stage localized PCa.(91) 
Post-hoc analysis revealed a stronger benefit in intermediate- compared to low-risk men. These 
findings were consistent with a smaller trial which randomized men to RT with versus without 
six-months of ADT and found a 15-year OS benefit.(90) A series of comparative outcome studies 
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based on retrospective data suggest benefit in survival for RP compared to EBRT and 
BT.(92,93,102,94–101) 
 Since RT and RP are not appropriate for all patients, certain circumstances warrant 
cryosurgery, HIFU and focal therapy. Recent guidelines for management of clinically localized 
PCa suggest cryotherapy may be appropriate in select patients depending on preferences, 
comorbidities and life expectancy.(90) Further, HIFU and focal therapy offer quality of life 
advantages to traditional approaches; however, studies comparing effectiveness with 
traditional approaches are lacking so are recommended to be offered only in the setting of a 
clinical trial.(90)  
 
1.5.3 High-Risk Prostate Cancer 
 
 Recommended therapy for high-risk PCa is RP or RT with ADT.(90) Results from the 
SPCG-4 trial have demonstrated benefit in OS and CSS for RP over watchful waiting.(87) Results 
from PIVOT indicated reduced metastases at 10 and 12-year follow up among those who 
underwent RP over watchful waiting, while men with high-risk disease specifically had a lower 
PCa-specific mortality rate (9.1% v 17.5%).(86) A randomized trial has shown benefit in clinical 
disease-free survival among locally advanced PCa patients receiving RT and ADT over RT 
alone.(103) Moreover, the rate of PCa-specific mortality among men with locally advanced PCa 
was elevated for those receiving short-term (6 months) compared to long-term (3 years) ADT 
(HR: 1.71 [1.14 – 2.57]).(104) OS and CSS were also improved among men with Gleason 8-10 
who were randomized to long-term compared to short-term ADT and RT (31.9% vs 45.1% and 
83.9% vs 88.7%, respectively).(105)  
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 Data comparing cryosurgery and traditional therapies (i.e., RP and RT) in high-risk 
patients is insufficient for the triage of patients between these two modalities.(90,106) 
Similarly, data comparing effectiveness between HIFU and traditional therapies is non-existent, 
while clinical studies vary in outcome reporting.(107) As such, guidelines recommend that these 
therapies be offered to high-risk patients only in the context of a clinical trial.(90) 
 
1.6 Gaps in Evidence Informing Care of Men Diagnosed with Unfavorable-Risk Prostate 
Cancer 
 
Despite the advances surrounding treatment selection and sequencing for unfavorable 
intermediate- and high-risk PCa noted above (referred to collectively as unfavorable-risk PCa), 
optimal initial therapy remains an area of intense academic and clinical debate.(108) The lack of 
clinical management clarity is due to barriers in obtaining high-quality evidence on the relative 
efficacy between common initial treatment options in the current era (i.e., RP and RT).(109) For 
instance, strong patient preferences surrounding RP and RT have resulted in numerous RCTs 
failing to accrue to completion, especially in North America.(110)(111) This occurs as RP is 
associated with increased rates of certain adverse functional outcomes, including erectile 
dysfunction,(88) and urinary incontinence,(112) while RT is typically associated with increased 
rates of urinary obstruction and irritation and bowel dysfunction and rectal bleeding.(113) Since 
most patients have strong preferences with regards to such outcomes, they generally decline 
randomization. 
In the absence of RCT data, multiple investigations have been performed to compare 
common treatment options using non-randomized data, which has its own 
challenges/limitations when trying to generate credible evidence to inform clinical practice. As 
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patients are not randomized, treatment assignment is influenced by both observed and 
unobserved factors that also influence relevant clinical outcomes of interest. For instance, 
candidates for RP compared to RT generally have less aggressive tumor characteristics, are 
younger and with fewer comorbidities.(114) This occurs as patients who are older, especially 
those with multiple comorbidities, are less suitable for RP because of peri-operative risks and 
delayed recovery.(115) As a result, these patients are more likely to be treated with RT. In 
addition, almost all patients are diagnosed with PCa by their urologists, and many are not seen 
by a radiation oncologist first to discuss management options. Since each specialist is more 
likely to recommend the treatment that they provide, candidates eligible for both RP and RT 
(i.e., younger patients with fewer comorbidities and less aggressive disease) are more likely to 
receive RP.(116) Age, comorbidity status and PCa aggressiveness are known to influence 
outcomes of interest negatively. As a result, patients undergoing RP are more likely to have 
better outcomes than those undergoing RT independent of treatment assignment. Crude 
categorization of confounders and/or not including all confounders in adjusted analyses and 
limitations in statistical adjustment can lead to improved CSS and OS among patients receiving 
RP compared to RT independent of treatment status.(117–120)  
Common endpoints used to compare treatment effectiveness in PCa also have potential 
for bias. As mentioned before, these include BPFS, metastatic progression-free survival (MPFS), 
CSS and OS. As mentioned previously, the definition of biochemical failure among patients 
treated with RP and RT differ. Since RP removes the whole prostate gland, it is anticipated that 
the prostate specific biomarker (used to define biochemical failure) maintain a non-significant 
value of <0.2ng/ml.(121,122) Since RT does not remove the gland, it is anticipated that some 
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prostate specific biomarker remains at significant levels of >2ng/ml above nadir.(61) The 
biochemical failure definition post-RP is intended to indicate cure whereas the definition post-
RT is sensitive and specific for future clinical outcomes of interest (e.g., distant 
failure).(123,124) These definitions represent different disease kinetics and outcomes and 
should not be compared in the context of comparative effectiveness research. Evidence of 
metastasis depends on the presence of prompts to image such as biochemical failure and 
symptoms. Prompts may differ depending on whether the patient underwent RP or RT and the 
frequency of follow-up, which is dependent on characteristics of the patient, physician, and 
treatment centre among other factors. Finally, PCa-specific mortality as ascertained by death 
certificates is not immune to bias. Death is sometimes misattributed to PCa among PCa patients 
who die of other causes.(125) This misattribution bias is more likely to occur among those with 
multiple comorbidities, as deciphering cause of death among multiple causes can be difficult. 
Since RT patients are more likely to have multiple comorbidities, this would negatively impact 
survival outcomes when compared with patients undergoing RP independent of treatment 
status. OS poses little concern for measurement bias, as causes of death do not have to be 
ascertained. 
Ascertainment bias can also influence treatment effect estimates. Consider a patient 
diagnosed with PCa and treated with RT. Diagnosis of PCa is accomplished through obtaining 
prostate tissue samples through needle biopsy to confirm the histopathological presence of 
cancer. In the case of a patient diagnosed with PCa and treated with RP, surgical resection of 
the prostate would allow for more thorough examination to detect any missed pathology on 
biopsy, resulting in upstaging of Grade Group.(126) As a result, patients undergoing RT may 
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harbor more aggressive cancer identified at diagnosis compared to patients undergoing RP. 
Consider comparing survival outcomes between a group of PCa patients treated with RT who 
received a diagnosis of Grade Group 1 (low-risk PCa phenotype) on biopsy with a group of PCa 
patients treated with RP who received a diagnosis of Grade Group 1 based on surgical 
pathology. Some patients in the RT group will likely harbor Grade Group 2 disease, which is 
associated with lower rates of survival while individuals in the RP group are unlikely to harbor 
Grade Group 2 cancer. As a result, patients treated with RP will appear to have better survival 
outcomes independent of their treatment. 
Finally, RT technology has evolved rapidly in recent years, such that observational data 
tends to reflect outdated regimens deemed less effective.(127)(128) Many authors have 
therefore discounted the results from such studies on the basis of irresolvable bias and 
technological drift.(108) Without relevant high-quality evidence, treatment decisions become 
more dependent on physician biases, differences in knowledge and experience as well as 
educational background. As such, it is important to address and account for identified sources 
of bias in observational studies and investigate modern RT approaches in relation to RP to 
improve evidence quality and credibility in guiding treatment decisions. 
 
1.7 Transition to Chapter Two 
 
 This chapter provided a review on the nature of PCa, basic Epidemiological information 
and approaches to identification of PCa through screening and diagnosis, categorization of the 
risk of PCa through risk-stratification and subsequent management options. The main thrust of 
this thesis, as per the title, is mitigating bias in PCa comparative effectiveness research. As such, 
a focus was placed on the bias associated with comparing the effectiveness of RT and RP as an 
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initial treatment for men diagnosed with unfavorable-risk non-metastatic PCa (i.e., unfavorable 
intermediate- to very high-risk non-metastatic PCa), as this is a substantial concern in the field 
of PCa comparative effectiveness research. The following chapter provided a review on popular 
methods in the management of confounding (i.e., both prevention through matching and 
control/adjustment through regression analysis) when performing comparative effectiveness 
research using non-experimental data. 
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Chapter 2: Background and Objectives 
 
2.1 The Value of Non-Experimental Data in Comparative Effectiveness Research 
 
Non-experimental comparative effectiveness research aims to generate evidence on the 
relative effectiveness and safety of different treatment approaches based on observations from 
routine clinical practice. This evidence can be used to identify more suitable treatment 
approaches for particular patients. Since the implementation of electronic patient health 
records, the proliferation of medical record and administrative claims databases has led to non-
experimental research occupying a large proportion of comparative effectiveness 
research.(129) Benefits attributable to large non-experimental databases include potentially 
increased power for statistical analysis, a broader range of patient characteristics (which can 
help enhance the applicability of results), longer follow-up periods (allowing for study of longer-
term outcomes), and the ability to address research questions that are impractical in the setting 
of a RCT.(129) Evidence from comparative effectiveness research using non-experimental data 
is also becoming increasingly implemented to guide clinical and policy decision-making based 
on the effectiveness and safety of treatments.(129)  
 
2.2 The Issue of Confounding in Non-Experimental Datasets 
 
Unlike in RCTs, subjects in non-experimental studies are not randomized to treatment 
groups; rather, treatment decisions are influenced by factors such as age, health status, disease 
severity, income, education, and patient and physician preferences, among other factors. These 
factors may also influence the occurrence/level of the outcomes of interest. As such, crude 
comparisons of the occurrence/level of the outcomes between treatment groups may not 
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reflect differences in effectiveness in the treatments under comparison. Factors that influence 
both treatment decisions and the occurrence or level of the outcome are known as 
confounders and must be accounted for when estimating treatment effects using non-
experimental data. 
 
2.3 The Counterfactual Theory for Valid Causal Inference 
 
The counterfactual theory for causal contrasts is a popular and useful framework for 
defining and addressing confounding in order to accurately estimate treatment effects.(130) 
The theory requires that in order to estimate a causal effect, we need to set up a valid causal 
contrast.(130) The ideal causal contrast is one where individuals from a population of interest 
that are exposed to a treatment of interest (index-treatment) are identical to those from the 
same population of interest but are unexposed or exposed to an alternative therapy used for 
comparison (reference-treatment). If this requirement is met, the observed variation in the 
outcome of interest is due to the difference in index- and reference-treatments. This 
relationship can be represented by the equation 𝐸[𝑌𝑖] = ∑(𝑌𝑖 − 𝑌𝑟)  wherein 𝐸[𝑌𝑖] denotes 
the expected mean index-treatment effect at the population level and Yi denotes the outcome 
in those who received the index-treatment and Yr denotes the outcome in those who received 
the index-treatment had they been exposed to the reference-treatment. Since the ideal causal 
contrast is not observed in reality, it is counter to what is factual, and must be estimated from 
available data.(131) The goal of comparative effectiveness research using non-experimental 
data under this framework then becomes estimating the average outcome among the 
 28 
reference-population to accurately estimate the counterfactual contrast in order to validly 
estimate index-treatment effects.  
The gold standard for estimating the counterfactual contrast is through a RCT. By 
randomizing individuals from a population of interest to index- and reference-treatments, each 
group contains individuals that, on average, share a similar distribution of baseline 
characteristics. As calendar time progresses, any variation in the presence or level of the 
outcome of interest observed between the index- and reference-treatment groups can be 
attributed to the difference in treatments. This assumes that drop-out between groups is non-
random/informative with regard to the outcome risk. The index-treatment effect can then be 
calculated through comparing the average outcome level between index- and reference-
treatment groups. This differs from the ideal measure in that no two individuals from different 
treatment groups will be identical, thus preventing us from calculating the individual index-
treatment effect. However, we expect that, on average, the distribution of characteristics 
between the two groups will be approximately the same, so most of the observed outcome 
variation that results between the groups can be attributed to the index-treatment. This 
enables us to estimate the average index-treatment effect rather than the individual index-
treatment effect (i.e., 𝐸[𝑌𝑖] = 𝐸[𝑌𝑖] − 𝐸[𝑌𝑟]). However, the average index-treatment effect is 
equal to the average of individual index-treatment effects. 
Hernàn and Robins outline three key conditions required to identify and accurately 
estimate the index-treatment effects under the counterfactual framework: exchangeability, 
positivity and consistency.(130) Exchangeability implies that if individuals from the reference-
treatment group were instead exposed to the index-treatment, we would observe the same 
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population effect as those in the index-treatment group and vice versa. That is, prognostically 
relevant characteristics (i.e., potential confounders) from the reference-treatment and index-
treatment groups are the same. Although in RCTs, random variability may introduce some 
imbalance in baseline characteristics between exchangeable groups, we anticipate that as the 
sample size grows larger, this imbalance dissipates and becomes less consequential. Positivity 
indicates that the probabilities of an individual receiving the index- or reference-treatment are 
both positive given their baseline characteristics (e.g., age, income, education, etc.) so that 
baseline characteristics that influence the outcome overlap between treatment groups. This is 
apparent in RCTs as the probability of receiving either treatment does not depend on individual 
characteristics but on a random process wherein each individual has an equal probability (e.g., 
0.5) of being assigned to either treatment. Finally, consistency indicates that the index- and 
reference-treatments, explicitly and clearly defined, are the same between individuals so that 
one individual does not receive a different intensity or timing of either treatment, thereby 
reducing outcome heterogeneity as a result of one index- or reference-treatment rather than 
multiple subtypes of either treatment. This is approximated in RCTs, to varying degrees, as each 
participant is expected to, thought does not always, adhere to the same treatment protocol. 
Since well-performed RCTs closely approximate these three conditions, they are 
regarded as the gold standard when making causal inferences. Unfortunately, RCTs are costly, 
time-intensive and often pose ethical constraints.(111) As a result, clinicians and policy makers 
often rely on evidence generated from non-experimental data, which tends to deviate 
substantially from all three principles of the counterfactual framework. For example, when 
trying to estimate index-treatment effectiveness using non-experimental datasets, those 
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receiving the index-treatment likely differ in important prognostic variables compared with 
those receiving the reference-treatment, thus deviating from exchangeability. Also, the reason 
some participants do not receive the index- or reference-treatment could be due to absolute or 
relative contraindications, thus deviating from positivity. Finally, the index- and reference-
treatments may vary in how they are delivered in terms of intensity, timing, and adjunctive 
therapies, thus deviating from the consistency condition. Issues of positivity and consistency in 
this scenario can be mitigated through restricting the analysis to only those eligible for both 
index- and reference-treatments who received similar exposure intensities, at similar times, 
and with similar adjunctive therapies. Exchangeability, however, remains as one of the most 
vexing issues in causal inference when using non-experimental datasets.(132) Lack of 
exchangeability can introduce confounding, since baseline characteristics that differ between 
treatment groups might also influence the outcome, making effect estimates inaccurate. 
 
2.4 Adjusting for Bias in Non-Experimental Data Using Regression Modeling 
 
Typically, when estimating the relative treatment effect, the occurrence/level of the 
outcome of interest would be modelled as a function of treatment received and potential-
confounding variables. Thus, a multivariable regression model would generally be fitted to 
estimate the regression coefficients for treatment received and potentially confounding 
variables through algorithms such as maximum likelihood estimation, among others.(133) The 
model fit could then be assessed through examination of residual plots and goodness-of-fit 
tests.(134) If the model fit was poor, modifications in the functional form of relation being 
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modelled could be made via adding higher-order terms for some characteristics, and/or 
interaction terms combining some independent variables. 
However, the occurrence or level of the outcome of interest could vary as a function of 
the confounding variables in a manner that does not tightly adhere to or is difficult to identify 
with functional forms or simple two-way interactions commonly used in health research. 
Inability to accurately quantify outcome variation attributable to confounding through 
appropriate modeling leads to residual confounding and biased effect-estimates.(135) 
Furthermore, since the functional form of the association of the study outcome with the 
treatment received and potential confounders can be specified to yield multiple models with 
reasonable fit, the model that is most consistent with the scientist’s hypothesis can be chosen. 
This is known as model dependence and increases the likelihood of falsely rejecting the null 
hypothesis, increasing the frequency of a type I error.(136)  
Issues of residual confounding and model dependence are further exacerbated with 
decreasing balance and/or overlap in the distribution of baseline covariates between treatment 
groups, as accurate estimation of regression coefficients becomes more reliant on model 
specification.(137) To explain, increasing imbalance in the multivariable distribution of baseline 
covariates increases the potential for confounding of effect estimates as treatment groups are 
not exchangeable. This can only be remedied through accurate model specification, which is 
dependent on overlap in the distribution, as the full range of values for each baseline covariate 
and combination of values for multiple baseline covariates must be observed in each treatment 
group (i.e., positivity) to accurately estimate regression coefficients. Otherwise, estimates for 
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regression coefficients rely on interpolation and extrapolation, which can lead to bias in effect 
estimates.(130) 
 
2.5 Preprocessing Non-Experimental Data to Improve Exchangeability and Positivity  
 
 To overcome these issues, data preprocessing techniques can increase the overlap and 
balance in the distribution of baseline covariates between treatment groups.(138,139)  
 
2.5.1 Preprocessing Non-Experimental Data Using Propensity Score Matching 
 
Propensity score matching (PSM) is an example of a data preprocessing technique that 
has become increasingly popular in recent years.(140) The propensity score (PS) can be defined 
as the probability of receiving the index- treatment given a subject’s baseline covariates.(141) 
Issues of missing data may prevent an accurate estimation of the PS. Matching subjects 
between treatment groups on the PS has the potential to balance observed baseline covariates 
between treatment groups and can thereby reduce, or even eliminate, confounding by those 
covariates.(141) This reduces reliance on model specification to control for confounding and 
thus reduces the potential model dependence.(138,139) However, unmatched subjects may 
systematically differ from those who remain in the matched sample. This has implications that 
limit the representativeness of the study population and the generalizability of the overall study 
findings. Further, confounding control through PSM is limited to observed covariates and may, 
in some circumstances, exacerbate hidden bias through furthering imbalance in unobserved 
confounders. Methods exist to overcome issues of unobserved confounding, including 
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instrumental variable approaches; however, are only effective when a valid instrumental 
variable exists for the causal contrast being considered.(134)  
Many studies demonstrate strong comparability in effect estimates produced from 
regression modeling with and without preprocessing by PSM.(142,143) However, PSM 
procedures are generally not performed optimally.(140) That is, systematic identification of 
PSM strategies that optimize balance in baseline covariates between treatment groups while 
retaining a sufficient sample size is not commonly done.(143,144) In one review, data were 
obtained from large RCTs where violations of positivity and exchangeability are not of 
concern,(143) thus limiting the ability of PSM to further reduce bias in effect estimates. 
Moreover, many authors do not control for residual confounding through multivariable 
regression modelling after PSM, leading to biased effect estimates.(140,142) 
Although PSM has many benefits when applied before regression modeling in the realm 
of comparative effectiveness research, King and Nielsen have recently identified a major issue 
in PSM that threatens the validity of treatment effect estimates.(136) Specifically, the “PSM 
paradox” is that as the strictness of the match (i.e., smaller allowed distance in the PS between 
matched individuals) increases, imbalance in baseline variables decreases until a certain point 
where imbalance begins to increase. This phenomenon occurs as matching on the PS does not 
use all the information from baseline covariates provided but rather takes an aggregate score, 
so it becomes incapable of discriminating between individuals who differ in individual or 
specific combinations of baseline covariates that are not captured in their PS. Once the PS 
extends beyond its means, increasing the strictness of the match increases imbalance through 
random elimination of individuals from the final matched cohort. Although concerning when 
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considering the increasing number of studies using PSM,(140) Ripollone et al rigorously 
reviewed the pharmacoepidemiology literature and did not find an empirical instance of the 
PSM paradox, but rather found all studies that used PS matching to have improved balance in 
baseline covariates between treatment groups.(145) 
 
2.5.2 Preprocessing Non-Experimental Data Using Coarsened Exact Matching 
 
 King and Nielsen recommend coarsened exact matching (CEM) as a superior alternative 
to PSM that uses information from all baseline covariates to decrease imbalance further than 
with PSM.(136) In this approach, continuous and ordinal characteristics are categorized, while 
some categories of inherently nominal characteristics get ‘collapsed’, resulting in fewer 
categories. In other words, CEM involves ‘coarsening’ of (at least some of) the potential 
confounders to facilitate the matching process. After variables are coarsened, multivariable 
strata containing observations from both treatment groups (i.e., areas of positivity) are 
retained, while the remaining strata are discarded. Index- and reference-treatments are 
defined, and a binary variable is adopted to represent the treatment group. Weights are then 
applied to each observation within each stratum to estimate the average treatment effect in 
the index-treatment group. This is accomplished with a weight of one for each observation 
remaining in the index-treatment group after matching. Weights for observations in the 
reference-treatment group are calculated as the proportion of total observations from the 
matched index-treatment group in a particular stratum (i.e., 𝑛𝑖𝑠/𝑛𝑖) divided by the proportion 
of total observations from the matched reference-treatment group in that same stratum ( i.e., 
𝑛𝑟𝑠/𝑛𝑟).(146)  
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A disadvantage to using CEM compared to PSM is that as the number of parameters 
increases, fewer matches become available unless the coarsening of parameters increases, 
which increases imbalance. Although PSM is not immune to this issue,(136) Elze and colleagues 
have demonstrated ability to balance baseline covariates between groups with as many as 17 
baseline covariates, while still retaining a substantial portion of the original population.(143) 
However, this was shown in an RCT, so it may have little applicability to non-experimental 
datasets where less overlap in the distribution of baseline characteristics is expected. Since 
much of the research on PSM and CEM has surfaced only recently, little evidence exists to 
support the use of either approach over the other in specific situations. 
Fullerton et al. examined the performance of different matching strategies in 
preprocessing non-experimental data, including PSM and CEM.(147) They found that although 
CEM improved balance in baseline covariates according to several measures of imbalance, it 
resulted in smaller matched subsamples that were not generalizable to the original cohort. In 
contrast, PSM led to improvements in only two of the three measures of imbalance but 
maintained the characteristics of the original cohort to a greater degree. Ripollone et al. also 
found that CEM was superior to PSM with regard to providing balanced covariate datasets 
according to the Mahalanobis distance measure.(148) However, CEM produced the least 
precise estimates due to lower levels of data retention after matching. Both comparisons used 
high-dimensional datasets with the smallest dataset involving 19 continuous and binary 
covariates and the largest having >100 covariates. Upon simulation analyses, Ripollone et al 
found effect estimates obtained through CEM maintained comparable precision to PSM in 
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lower dimensional datasets involving 8 covariates, while providing more balance in baseline 
covariates between comparison groups. 
Major limitations in these studies that hinder the validity and applicability of their 
results should be noted. First, neither study used a systematic approach to identifying and 
evaluating PS models that optimize data retention and balance. They also did not evaluate 
different matching ratios or caliper widths when using PSM, which has a potential to further 
improve balance between groups and precision in the effect estimate.(144) Third, both 
comparisons used high-dimensional empirical datasets with the smallest dataset involving 19 
continuous and binary covariates and the largest having >100 covariates. Fourth, they often 
relied upon quantile-based rules for coarsening continuous variables, such as Sturges’ rule.(149) 
In contrast, in many areas of comparative effectiveness research, the number of baseline 
covariates that consistently influence treatment decisions and are associated with important 
outcomes is relatively small;(144,150) furthermore, there often is a priori information on the 
prognostic value of continuous and ordinal variables that can allow one to create more 
prognostically meaningful strata rather than strata formed from quantile-based rules, which 
may not align. This can lead to retention of observations from the index-treatment and 
reference-treatment groups in the same strata that have distinguishable clinical prognoses. 
Moreover, index-treatment and/or reference-treatment observations with similar prognoses 
that do not fall into quantile-based strata might be lost. Overall, retention of observations with 
distinguishable clinical prognoses and loss of observations with similar prognoses reduces 
potential balance and levels of data retention, respectively, that could be achieved if ranges of 
baseline covariate values were informed by prior evidence on prognosis. Finally, Fullerton et al 
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and Ripollone et al did not control for residual confounding through multivariable regression 
modelling after matching, which is recommended to control for remaining bias after 
matching.(140,142) 
 
2.6 Transition to Chapter Three 
 
This chapter provided a review of the value of evidence produced from non-
experimental data in informing treatment decision making. Importance was placed on the 
concern for bias through confounding in evidence produced from non-experimental data. The 
counterfactual theory was reviewed to provide a theoretical basis from which to discuss the 
ability of popular statistical techniques in preventing (i.e., PSM and CEM) and adjusting for (i.e., 
regression modeling) confounding when estimating treatment effects and their associated 
shortcomings. Although previous studies have compared PSM and CEM in the prevention of 
confounding when estimating treatment effects using non-experimental data, several 
shortcomings in these comparisons were noted. In particular, there was a lack of a systematic 
approach to developing and evaluating PSM and CEM strategies that optimize data retention 
and balance.  
Chapter three provides a review of diagnostics used to assess balance in the 
multivariable distribution of baseline covariates when comparing treatment outcomes using 
non-experimental data. A sufficient set that captures important differences in the distribution 
of baseline covariates with potential to introduce confounding, according to the counterfactual 
theory, is recommended to evaluate the success of matching in preventing confounding. This 
groundwork was necessary to inform the systematic approach to developing and evaluating 
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PSM and CEM strategies that optimizes data retention and balance between treatment groups 
obtained from non-experimental data covered in chapter four. 
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Chapter 3: Assessing the Potential for Confounding through Balance 
Diagnostics 
 
To compare the performance of matching strategies in the ability to balance treatment 
groups, the appropriate metric should be used. Many methods have been developed to assess 
comparability between baseline covariates between exposure groups after matching. These 
methods are generally termed “balance diagnostics”.(151) All balance diagnostics have a similar 
goal: to quantify the difference in the multivariate distribution of baseline covariates between 
treatment groups in order to measure the degree of exchangeability. A common approach to 
quantifying balance is to compare means and/or medians of continuous variables and the 
distribution of categorical variables in index- and reference-treatment groups.(152) This 
approach is in line with the CONSORT statement, which requires that authors provide a 
summary table of the baseline characteristics in different treatment arms.(153) Comparison of 
continuous variables using a t-test and dichotomous variables using a chi-square test have been 
proposed and are most commonly utilized in non-experimental comparative effectiveness 
research.(153) However, these are not appropriate when performing adjustment techniques 
that reduce the sample size (i.e., matching). Since these tests are dependent on sample size, as 
the number of subjects who are not eligible for matching increases, the sample size in each 
group decreases, increasing the likelihood of a non-statistically-significant difference in baseline 
covariates, irrespective of whether balance actually improves (Figure 3.1).(154)  
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Figure 3.1  (a) the t-statistic 
comparing difference in means 
between treatment and control 
groups decreases as control units 
are randomly dropped; (b) 
indicates a constant difference in 
means and quantile–quantile plot 
mean deviation between treatment 
and control groups as control units 
are randomly dropped.(154) 
 
 
3.1 Balance Diagnostics for the Central Tendency of Single Variables 
 
Another approach to comparing the difference in means and proportions between 
treatment groups involves calculating the standardized mean difference (SMD).(152) This has 
become the standard approach, as the SMD is easy to compute and understand,(155) while 
being independent of sample size. Moreover, it allows for the comparison between covariates 
with different units since the SMD is unitless. For continuous variables, this can be calculated as 
the quotient of the difference in means between groups in the numerator and the root of the 
average of the sample variance in each group in the denominator. For categorical variables, this 
can be calculated as the quotient of the difference in proportions between groups in the 
numerator and the average of the variance in sample proportions in each group in the 
denominator. 
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Peter Austin shows that when the SMD <0.1, the amount of non-overlap in the baseline 
covariate between groups is <7.7%, indicating a high-degree of comparability.(152) However, 
this is based on several assumptions including that the covariate under investigation is normally 
distributed with equal variance between the two treatment groups being compared and that 
groups have similar sample sizes. Although such a difference might seem negligible, it is 
important to consider the prognostic association of the baseline variable. For example, if the 
association is non-linear then confounding can still manifest when SMD <0.1 since a greater 
proportion of one group might occupy greater levels of the confounding variable with greater 
prognostic value, while the other group clusters around the mean. Stuart et al. performed 
multiple data simulations with varying confounder relationships between a binary treatment 
and continuous outcome.(156) They found that both the correlation between the mean SMD of 
all confounders or proportion of confounders with SMD <0.1 and the true bias was stronger 
among simulations limited to continuous confounding variables with linear main effects 
compared with simulations involving both continuous and categorical confounding variables 
with non-linear effects. This indicates that small values of SMD do not necessarily indicate 
comparability, especially among covariate structures involving categorical and non-linear 
continuous variables, which are common in the medical literature. 
 
3.2 Balance Diagnostics for the Variance of Single Variables 
 
Imai et al. suggest that higher order moments of the baseline covariate distributions 
between treatment groups be compared in order to address this potential issue.(154) After the 
mean, which indicates the central tendency of the distribution, the variance, which indicates 
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the amount of deviation, is the second moment in the covariate distribution. As such, 
estimating the ratio of variances in baseline covariates between groups in addition to SMD has 
been recommended.(152) Peter Austin demonstrated that under the null hypothesis, the 95% 
confidence interval for equality in variances between two independent groups amounts to a 
lower bound of approximately 0.92 and an upper bound of 1.08.(152) This was derived from a 
data simulation study of 2430 matched pairs and an F-distribution with 2429 and 2429 degrees 
of freedom so has limited applicability in different settings. Imai et al., have suggested quantile-
quantile plots for comparison of the distribution of continuous covariates for assessing balance 
between two groups.(154) As such, comparing both the variance ratios and quantile-quantile 
plots can assist in identifying any notable differences between exposure groups. 
 
3.3 Limitations of Balance Diagnostics for Single Confounding Variables 
 
 Thus far, we have discussed imbalance in single covariates, which has only the potential 
to assess main effects of confounding. However, most comparative effectiveness research 
includes multiple baseline covariates that have potential for confounding. As the number of 
baseline covariates increases, the amount of potential bias increases even when SMD <0.1 and 
the variance ratio is between 0.92 and 1.08. Moreover, other aspects of multivariable 
distributions between comparison groups could differ on the basis of covariance between 
multiple confounding variables, which might indicate different levels of effect modification at 
the level of confounding between comparison groups. Small differences in SMD and variance 
ratios in many baseline covariates coupled with differences in covariance have potential to bias 
treatment effect estimates in the presence of “balanced” baseline covariate distributions as 
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commonly defined by the “acceptable” ranges of SMD and variance ratios.(155,156) For 
instance, Stuart et al found that the correlation between true bias and measures of imbalance 
based on SMD, as described above, became weaker when their data simulations involved an 
interaction effect between confounding variables compared to main effects alone. This issue 
can be overcome through calculating the SMD for appropriate interaction terms;(152) however, 
such interaction is not always easily identifiable in real datasets. Moreover, interactions 
between two variables can vary according to a third,(157) which makes identification of 
appropriate interaction terms for assessing balance more complicated. 
 
3.4 Prognostic Scores 
 
Stuart et al propose checking balance by examining SMD in a prognostic score.(156) This 
is accomplished by first identifying prognostic factors through a thorough examination of the 
literature and expert consultation. The outcome of interest is then modelled as a function of 
the prognostic variables using the referent category under comparison in order to obtain the 
estimated baseline prognosis in the absence of the index-treatment. Using this model, the 
predicted prognosis is estimated for each individual in the index- and reference-treatment 
groups to derive their “prognostic scores”. The SMD in prognostic scores between groups is 
then calculated to obtain estimates of balance. Compared to a number of other balance 
diagnostics, including mean SMD and proportion of SMD <0.1, the SMD in prognostic score 
consistently obtained stronger correlations with true bias in most situations (>0.90). However, 
this was dependent on whether the true prognostic score was appropriately specified. In 
situations where the prognostic score was not appropriately specified, the correlation between 
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the SMD in prognostic score with the true bias were as low as 0.31. Since the true prognostic 
score might involve many regression coefficients, estimation in smaller datasets may be 
unreliable, leading to improperly estimated prognostic scores and thus unreliable measures of 
imbalance. One way to overcome this is to use validated prognostic scores. For example, in PCa 
research, as mentioned in chapter one, risk-groups, reflecting different prognoses post-
treatment, have been identified as one of the most reliable predictors for biochemical 
progression, which is an important oncological outcome.(158) The SMD in the proportion of 
observations occupying different risk-groups are used in chapter four as the SMD in prognostic 
scores. 
 
3.5 Global Imbalance Measure 
 
 One way to overcome the issues of assessing balance in multiple covariates and their 
relationships between one another as well as model dependence would be to calculate the 
distance between multivariate distributions between comparison groups. This can be 
accomplished using the global imbalance measure (L1) developed by Iacus et al.(159) In this 
approach, each variable whether continuous or categorical are stratified using bounds that 
define acceptable levels of variation based on previous research.  
The stratified covariates can be cross tabulated to create multidimensional histograms. 
The absolute difference in multidimensional histograms divided by two provides an estimate of 
global imbalance between groups (L1), as demonstrated below: 
ℒ1(𝑓, 𝑔; 𝐻) =
1
2




Wherein f and g denote the relative empirical multivariable frequency distributions for the 
index- and referent-units, respectively, and 𝑓𝑙1…𝑙𝑘 and 𝑔𝑙1…𝑙𝑘denote the relative frequency for 
observations belonging to the cell with coordinates 𝑙1 … 𝑙𝑘  of the multivariable cross-
tabulation.(159) This can be interpreted in that if two empirical distributions are completely 
separated, then L1=1 and there is 0% overlap between the two groups with regard to the 
multivariate distribution in baseline covariates. If the two distributions are the same, L1=0 and 
there is 100% overlap in multivariable distribution between the two groups. 
In theory, the global imbalance measure appears superior to other balance diagnostics 
in its ability to adequately capture all bias due to differences between groups in single 
covariates and any interaction among two or more covariates. However, data simulations have 
demonstrated that decreasing bias associated with improvements in covariate balance are not 
strongly correlated with reduction in the global imbalance measure.(160) These findings are 
consistent when trying to balance covariates using cohort data in that improvements in balance 
in prognostic covariates are not strongly correlated with reduction in the global imbalance 
measure.(147) This might occur as it does not weigh covariates and their interactions according 
to their prognostic value but rather measures all imbalances in the multivariable distribution 
equally important. This is further emphasized by Belitser et al. who demonstrated that when 
weights were applied to balance diagnostics to represent their prognostic value, the negative 
correlation between balance and bias became stronger.(161) 
The absence of a strong correlation between the global imbalance measure and bias 
limits the utility of it as an imbalance measure. For instance, when optimizing matching 
algorithms to improve baseline covariate balance between exposure groups and thus reduce 
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bias, changes in balance diagnostics sensitive to improvements in covariate balance are helpful 
to identify the matching algorithm capable of reducing the most imbalance given a level of data 
retention. As such, the global imbalance measure has limited utility in assessing bias due to 
covariate imbalance in the context of causal inference using nonrandomized data. 
 
3.6 Other balance diagnostics 
 
Although other measures of imbalance exist such as the Kolmogorov-Smirnov distance, 
the Lévy distance, and the overlapping coefficient, previous studies have demonstrated weaker 
correlation with bias in addition to theoretical limitations that make them less informative and 
suitable.(152,160,161) As such, these imbalance measures are not considered. 
 
3.7 Recommended use of balance diagnostics for development and evaluation of the PS 
model in PSM 
 
Herein, we recommend a set of balance diagnostics to measure all imbalances in the 
multivariable distribution with prognostic value when comparing treatment effectiveness from 
non-experimental data. Since the average absolute SMD of all baseline covariates reflects 
balance in typical values that are deemed most important, it should be used to evaluate general 
improvements in balance as the width of the PSM caliper decreases. However, since the 
average absolute SMD might decrease, while the absolute SMD of individual covariates might 
increase, we also propose that the number of individual covariates with |SMD| <0.1 be 
measured to ensure no gross imbalance in any single variable. Likewise, to capture general 
improvements in balance for higher-order moments, the average of variance ratios for 
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continuous variables can be monitored in conjunction with the number of variables falling 
below 1.08 (if ratio is <1.00 then take the reciprocal) to ensure no gross violations in the second 
moment of individual covariate distributions.(152) Finally, a validated prognostic score should 
be used to capture important combinations of covariate values that might be missed. If no 
validated prognostic scores are available, one can estimate a prognostic score from their 
dataset using methods established by Stuart et al,(156) provided there are a sufficient number 
of events and non-events available. 
 
3.8 Transition to Chapter Four 
 
This chapter provided a review of balance diagnostics and their relative informativeness 
with regard to assessing the potential for confounding when comparing treatment outcomes 
using non-experimental data. A recommended set of diagnostics was identified that 
comprehensively evaluates differences in the multivariable distribution of baseline covariates 
with confounding potential. The following chapter demonstrates how to use the recommended 
set of balance diagnostics to guide the development of a propensity score model for matching 
that optimizes efficiency with respect to balance achieved in the multivariable distribution as 
well as retention of observations from the original dataset. 
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Chapter 4: A Systematic Approach to Developing and Evaluating 
Propensity Score Models for Matching 
 
 Despite the existence of multiple guidelines on how to perform PSM in comparative 
effectiveness research,(162–164) information surrounding the use of balance diagnostics in 
guiding the development and evaluation of PSM strategies remains elusive and subject to 
criticism. For example, most guidelines for clinical researchers emphasize the use of a 
standardized caliper (e.g., 0.2 of the standard deviation of the logit of the PS) for matching 
strategies and recommend iteratively exploring balance achieved after matching as a diagnostic 
tool for adequacy of the PS model.(162–166) However, the performance of different PS models 
used in matching depends on the balance diagnostic used for assessment (e.g. standardized 
mean difference (SMD), variance ratio, etc.) and caliper size. For instance, one PS model might 
lead to better balance than some alternative model given certain combinations of caliper sizes 
and balance diagnostics but to worse balance when compared to the same alternative given 
different balance diagnostics and caliper sizes. 
Moreover, the balance diagnostics recommended by such guidelines often do not 
capture all differences in the multivariable distribution of baseline covariates between 
treatment groups. Often, the SMD is recommended to evaluate the differences in the central 
moment and, sometimes, the variance ratio to evaluate higher-order moment of imbalance in 
the distribution of individual covariates. As mentioned in chapter three, these balance 
diagnostics neglect important interactions that hold prognostic value about the outcome of 
interest and thus have potential to confound associations even in the presence of balanced 
individual covariates.  
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In this chapter, we offer a systematic approach to developing and evaluating PS models 
used in matching that maximize balance in all key aspects of the multivariable distribution to 
mitigate potential for confounding, while also maximizing retention of observations from the 
original dataset. A working example is provided from the PCa literature.  
 
4.1 Working Example: Comparing the Rates of Biochemical Failure between Different 
Radiotherapy Approaches for Prostate Cancer 
 
4.1.1 Background and Data Source 
 
Different approaches to RT are available for the treatment of PCa.(2) BT involves the 
insertion of a radioactive isotope into the prostate gland.(3) Compared with the EBRT, BT is 
capable of delivering greater doses of radiation to the prostate gland while sparing adjacent 
structures such as the rectum and bladder.(4) As such, it is generally reserved for the 
monotherapy of tumors that maintain a lower-risk of extraprostatic extension unless it is 
combined with EBRT for higher risk situations.(4) Risk of extraprostatic extension is estimated 
by consideration of PSA, GS, and cT stage.(5) These characteristics also hold considerable 
prognostic value regarding important oncological outcomes such as BPFS, MPFS, CSS and OS.(6) 
Thus, when comparing BT with EBRT, it is important to adjust for all of these factors, among 
other baseline patient characteristics.  
 For this demonstration, we abstracted data from the Prostate Cancer Risk Stratification 
(ProCaRS) database. This database contains data on 7974 patients diagnosed with PCa and 
treated with different forms of primary RT between 1994 and 2010 from four Canadian 
institutions in Toronto, Quebec City, Montreal and Vancouver.(144) Details regarding ethics 
 50 
approval, database construction and quality assurance have been previously described.(20) The 
example comparison for our approach was informed by a RCT performed by Morris and 
colleagues, which compared the rate of biochemical failure among men diagnosed with 
intermediate-risk PCa according to the National Comprehensive Network and treated with 
either BT and hormone therapy (BT) or EBRT and hormone therapy (EBRT).(167) In this trial, the 
authors found an increased incidence of biochemical failure in the EBRT relative to the BT group 
(hazard ratio [95% confidence interval]: 2.04 [1.25, 3.33]). 
 
4.1.2 Descriptive Measures 
 
 We begin with an initial examination of characteristics in the unmatched samples from 
the ProCaRS dataset. Table 4.1 shows that the BT group was, on average, treated at earlier 
dates than the EBRT group (median treatment year of 2002 vs 2003, respectively), and had less 
advanced tumor characteristics, as expected. 
Table 4.1 Descriptive statistics and balance diagnostics for unmatched BT and EBRT samples 
 BT (n=433) EBRT (n=132) |SMD| Variance 
Ratio 
RT Start Year 
Median 2002 2003 0.3029 1.49 
IQR 2001, 2004 2002, 2004   
PSA (ng/ml) 
Median 7.60 9.02 0.3468 1.60 
IQR 5.70, 10.50 5.88, 12.60   
Clinical T-Stage 
T1a-2a 373 86.14% 122 92.42% 0.2041  
T2b-c 60 13.86% 10 7.58%   
Gleason Grade 
1 126 29.10% 23 17.42% 0.2790  
2 249 57.51% 64 48.48% 0.1815  
3 58 13.39% 45 34.09% 0.5014  
PROCARS Risk-Group 
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Low-intermediate 404 93.30% 99 75% 0.5177  
High-intermediate 29 6.70% 33 25%   
 Average 0.2936 1.29 
 
 Table 4.1 also shows that the two groups are imbalanced with regard to the SMD for 
individual covariates, and risk-group as well as the average absolute SMD for all covariates. The 
average variance ratio and individual variance ratios were also greater than the accepted 
threshold of 1.08. 
 
4.2 Model Development 
 
In developing PS models, we propose beginning with more general models (i.e., using 
simple linear terms for continuous covariates, original categories for categorical variables and 
without interactions) and increasing the complexity to better fit the relation between 
treatment predictors and treatment received by adding higher-order and interaction terms. 
Here, we use a logistic model to specify our PS. Since power is driven by the smaller comparison 
group, we would like to optimize retention of the smaller group. In this case, EBRT is the smaller 
group, so treatment status is coded as EBRT = 1 and BT = 0.  
 
4.2.1 Model One 
 
The first model involved simple linear terms for continuous characteristics and ‘dummy’ 
variables to represent categorical characteristics. The reader is referred to an article by 
Brookhart et al for an in-depth discussion on covariate selection in PS models.(168) In brief, it is 
recommended that any variable notably associated with the outcome be included to enhance 
precision and accuracy in effect estimates. The term ‘PSA’ in model one represents the 
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regression coefficient for baseline PSA (ng/ml), ‘GS’ represents the regression coefficient for 
Gleason score, ‘TS’ represents the regression coefficient for clinical T-stage, ‘TxYr’ represents 
the regression coefficient for year that RT was initiated. We specify a logistic regression model 
with treatment as the dependent variable using the ‘glm’ (or generalized linear model) 
command with ‘family=binomial’ option in RStudio.(169) 
 
> model1 <- glm(Tx ~ PSA + GS + TS + TxYr, data = PROCARS, family = "binomial") 
 




] = 𝛽0 + 𝛽𝑃𝑆𝐴x𝑃𝑆𝐴 + 𝛽𝐺𝑆x𝐺𝑆 + 𝛽𝑇𝑆x𝑇𝑆 + 𝛽𝑇𝑥𝑌𝑟x𝑇𝑥𝑌𝑟 
 
4.2.2 Model two: Identifying departures from linearity and improving functional form in the 
relation between continuous predictors and treatment received 
 
The second model attempts to improve the accuracy of the PS in predicting the 
treatment received through improving model fit of the functional form of the relation between 
continuous covariates and treatment status. To identify departures from linearity in the 
relationship between continuous predictors and the logit of the probability for receiving the 
treatment of interest, locally weighted scatterplot smoothers can be used. Evaluation of 
whether proposed transformations using higher-order terms improve model fit can be verified 
using the likelihood-ratio test for nested models and the pseudo-R2 for both nested and non-
nested models.(134) In our example, we found that a restricted cubic spline for baseline PSA 
(‘rPSA’) and categorization of treatment start date into two-year increments (‘TxYr2’) improved 
model fit,(134) which was confirmed using the likelihood ratio test (p=0.00052) and pseudo-R2 
(model one = 0.13 vs model two = 0.17). As such, we added these terms to our second model: 
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> model2 <- glm(Tx ~ PSA + rPSA + GS + TS + TxYr2, data = PROCARS, family = "binomial") 
 
 
4.2.3 Model Three: Identifying interaction terms 
 
Finally, the third model attempts to improve accuracy of the PS in predicting the 
treatment received through identifying interaction terms between independent variables that 
improve model fit. Again, improvements in model fit can be verified using the likelihood-ratio 
test and pseudo-R2 value. In the example provided, all two-way interactions among 
independent variables were assessed and a notable improvement in model fit relative to model 
two (likelihood ratio test p=0.0057 and pseudo-R2 = 0.18) was found with the addition of an 
interaction term between baseline PSA and Gleason score, represented by the ‘PSA*GS’ term, 
which was added to our third model: 
> model3 <- glm(Tx ~ PSA + rPSA + PSA*GS + GS + TS + TxYr2, data = PROCARS, family = "binomial") 
 
 
4.3 Propensity Score Matching Characteristics 
 
Now that multiple candidate PS models have been specified, decisions regarding 
matching algorithm, matching ratio, and caliper size must be made. The most common 
combination involves the use of nearest-neighbor matching with select caliper width and 
without replacement.(170) That is, a random exposed subject is matched to an unexposed 
subject with the most similar propensity score (i.e. nearest-neighbor) who has a predicted PS 
within a pre-specified range of the exposed subject’s PS (i.e. caliper). After the unexposed 
subject is matched, they are removed as a candidate for further matching (i.e., without 
replacement). This is often done in a one-to-one fashion; however, depending on the 
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proportion of exposed to unexposed subjects, many to one or one to many might be ideal. In 
our example, there are approximately 3.3 BT observations for every one EBRT observation. As 
such, a matching ratio of 3:1 BT to EBRT observations might be favorable to maximize retention 
of BT observations. Other methods of matching involve nearest-neighbor matching without 
calipers, optimal matching wherein exposed and unexposed subjects are matched so as to 
minimize the total within-matched PS difference, and full-matching. The reader is referred to 
another guideline that reviews these matching algorithms thoroughly.(163)  
Caliper size impacts variance and bias in the effect estimate as well as how baseline 
variables are balanced in the final model. A smaller caliper size will reduce the number of 
observations matched, thus eliminating more subjects from the final matched sample, while 
larger calipers will have the opposite effect. This ultimately impacts precision of the effect 
estimate with larger and smaller calipers generally leading to more and less precise effect 
estimates, respectively. Bias increases with caliper size as larger calipers enable more dissimilar 
subjects to be matched. Thus, when selecting caliper widths, a balance must be achieved 
between precision and validity of the effect estimate.  
Popular calipers include fixed widths of the PS as well as a function of the logit of the 
propensity score (Logit(PS)), as the logit is more likely to approximate a normal distribution 
than the probability metric. Cochrane and Rubin have demonstrated that matching on a 
normally distributed confounding variable with caliper widths of 0.6 and 0.2 standard 
deviations (SD) of the Logit(PS) can remove 90% to 99% of confounding for that particular 
variable, respectively.(171) However, the caliper width that optimizes the balance between bias 
and precision will depend on the characteristics of the dataset (i.e., the multivariable 
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distributions of baseline covariates in the treatment groups). As such, we propose that analysts 
start with wider calipers and explore progressively more narrow calipers to identify a ‘plateau’ 
in the association between improvements in balance and retention of the original dataset. The 
plateau is operationally defined as the point where further decreasing the PSM caliper leads to 
negligible improvements in balance, while leading to further decreases in data retention. The 
concept of a plateau will be demonstrated in the section 4.4. 
 We used the ‘MatchIt’ package in R to perform matching strategies with nearest-
neighbor matching (R input option: method="nearest") as the algorithm,(146) a matching ratio of 
3:1 for BT:EBRT (R input option: ratio = 3), matching BT to EBRT observations, without 
replacement (R input option: replace = FALSE), and with progressively more narrow calipers (R 
input option: caliper = 0.1). An example is given below: 
psmatch<-matchit(Tx ~ BasePSA + cGS + cTS + TxYr, data=PROCARS, method="nearest", ratio = 3, caliper = 
0.1,  replace = FALSE) 
 
4.4 Evaluating Model Performance 
 
To evaluate the performance among candidate PS models used in matching, we propose 
that the efficiency of the candidate models be compared. Efficiency, as defined here, is the 
amount of balance improvement for a given level of the original population retained. Measures 
of SMD, and variance ratios can be obtained through the cobalt package in R.(172) Afterward, 
measures can be examined graphically using plots with the balance achieved through PSM for 
each candidate PS model for a given percentage of the original population retained. In other 
words, the PS model that leads to better balance among all diagnostics with the same or 
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greater percentage of the original population retained is deemed the most efficient PS model 
and will be the selected model based on this performance. 
 
4.4.1 Identifying the most efficient caliper width to compare efficiency between PS models 
 
A standardized rule for identifying a specific caliper width is required to compare the 
efficiency of each candidate model. We propose that the point at which further narrowing PSM 
calipers for each PS model leads to a ‘plateau’ be used for this purpose. That is, when further 
narrowing the matching caliper leads to negligible improvements in or worsening balance at the 
expense of a decrease in the percentage of the original population retained. In our example, we 
explored balance achieved after matching without a caliper wherein the nearest-neighbor 
referent-unit of a randomly selected index-unit is matched and this process is repeated until 
each index-unit is matched with the specified number of referent-units. After, we matched with 
caliper limits of 2.0, 1.5, 1.0, 0.8, 0.6, 0.4, 0.3, 0.2, 0.1, 0.05, 0.025, 0.02, 0.015 and 0.01 
SD(logit(PS) to capture the plateau. Using model one from our example and looking from right 
to left, we see that the average SMD plateaus at approximately 70% retention (Figure 4.1). This 
corresponds to a plateau in the average variance ratio (Figure 4.2) and risk-group SMD (Figure 
4.3). We can also see at approximately 40-50% data retention, what King and Nielsen have 
termed, the PSM paradox where decreasing caliper size paradoxically leads to increasing 
imbalance.(136) The caliper width of 0.1 standard deviations of the logit of the PS, which leads 
to approximately 67% retention of the original cohort and plateau in all balance diagnostics 
appears to be the most efficient PSM strategy using model one. Likewise, a caliper width of 0.1 
standard deviations of the logit of the PS for models two and three, which lead to 
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approximately 66% and 63% retention of the original cohort, respectively, lead to a plateau in 
balance reduction for all balance diagnostics. 
 
Figure 4.1 Association between percent of original population retained and average 











































Figure 4.2 Association between percent of original population retained and the average 












































Figure 4.3 Association between percent of original population retained and the risk-









































4.4.2 Comparing balance after matching on candidate PS models 
 
Given the similar percentage of retention among all matching strategies at the 
previously selected caliper width, we can compare the balance achieved in our five balance 
diagnostics between our candidate models (Table 4.2). The first model leads to an average 
absolute SMD of 0.027 with no covariate SMD>0.1, average variance ratio of 1.39 with both 
continuous variable variance ratios >1.08, and a risk-group SMD of 0.22. The second model 
leads to an average absolute SMD of 0.027 with no covariate SMD>0.1, average variance ratio 
of 1.08 with one continuous variable variance ratio >1.08, and risk-group SMD of 0.098. Finally, 
the third model leads to an average absolute SMD of 0.030 with no covariate SMD>0.1, average 
variance ratio of 1.04 without either continuous variable variance ratio >1.08, and risk-group 
SMD of 0.046. The second and third model led to better overall balance with the third 
outperforming the second. As a result, the third model provided the most efficient matching 
strategy in comparison with models one and two.  
Table 4.2 Comparison of the percentage retained in the original cohort and balance in baseline 













covariates with a 
variance ratio >1.08 
Risk-group 
SMD 
1 67.3 0.027 0 1.39 2 0.22 
2 66.0 0.027 0 1.08 1 0.098 




 In this section, we review the strengths of this approach in light of previous guidelines. 
The standardization in developing and evaluating PS models used for PSM in comparative 
effectiveness research helps reduce researcher bias. To explain, since multiple combinations of 
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PS models and caliper widths might lead to “reasonable” balance, and effect estimates 
randomly vary, the combination of a particular PS model and caliper width that led to an effect 
estimate more in-line with the scientist’s hypothesis can be chosen. Although this is still 
possible with our approach, it is considerably more limited since there will be fewer available 
options. Second, the set of balance diagnostics proposed is comprehensive in evaluating 
multiple characteristics of the multivariable distribution in baseline covariates that have 
potential to confound effect estimates based on the counterfactual theory of causal contrasts. 
Obtaining balance in this set of diagnostics offers more convincing conclusions regarding 
relative treatment effectiveness from which to base patient- and policy-level decisions. 
Compared to previous suggestions of iteratively exploring random combinations of PS models, 
and calipers, our systematic approach to identifying the most efficient caliper width associated 
with each PS model after matching allows the most efficient approach to identifying the PS 




 In this section, we discuss some limitations to the proposed approach that might arise 
with different datasets and offer potential solutions. One concern is if a plateau occurs in one 
balance diagnostic at a different level of data retention than another balance diagnostic (e.g., 
stabilization in the average absolute SMD occurs at approximately 80% data retention but 
occurs at 70% for the average variance ratio and 60% with the prognostic score based SMD). In 
this scenario, if the level of balance remains stable with progressively narrower calipers in the 
balance diagnostics that plateau first, the point at which the other balance diagnostics plateau 
should be used as the most efficient caliper width for comparison. If the level of balance 
 62 
worsens with progressively narrower calipers in the balance diagnostics that plateau first, 
multiple calipers consistent with each plateau in each balance diagnostic should be used for 
comparison. This might lead to two sets of matched samples for comparison generated from 
two caliper widths if the plateau occurs at a different data retention level for only one balance 
diagnostic or three sets of matched samples for comparison generated from three caliper 
widths if the plateau occurs at different data retention levels for all balance diagnostics. A 
reasonable alternative to this approach might include a caliper that leads to a mid-level of 
balance in all diagnostics for the same level of data retention. Inevitably, there will always be 
some exceptions where these rules will not apply, and the analyst will need to formulate their 
own decision. It is recommended that the rationale for such a decision be transparent to allow 
the reader sufficient information to evaluate the reasonableness of the decision. In addition, 
the author should report results from other reasonable matching strategies to demonstrate 
consistency in effect estimates.  
 
 4.7 Summary 
 
In summary, we propose that a set of balance diagnostics that sufficiently capture 
important differences in the multivariable distribution be used in a systematic approach to 
developing and evaluating PS models used for PSM. We invite criticism and commentary 
surrounding the approach developed and presented here to improve the conduct and reporting 
of PSM for observational data in comparative effectiveness research. Since RCTs are becoming 
increasingly more difficult to perform due to multiple available standards of care with varying 
characteristics that preclude randomization for ethical and financial reasons, the accuracy of 
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evidence produced from observational datasets is becoming increasingly important to guide 
patient- and policy-level decisions. As such, improvements in this field hold considerable value 
to researchers, clinicians, and patients alike. 
 
4.8 Transition to Chapter Five 
 
 This chapter provided a systematic approach to developing and evaluating propensity 
score models for matching that optimizes balance in the multivariable distribution of baseline 
covariates and data retention. Improvements in balance per amount of data retained were 
achieved in models involving higher order terms for continuous covariates and interaction 
terms between some terms relative to simpler models. This shows that previous guidelines for 
developing models used in propensity score matching are inadequate and highlights the need 
to assess model performance using multiple balance diagnostics in a systematic fashion that 
also evaluates data retention.   
The systematic approach to developing matching strategies is used in the following 
chapter to compare the performance of propensity score matching and coarsened exact 




Chapter 5: Comparing the performance of coarsened exact matching 
and propensity score matching in non-experimental prostate cancer 




In this chapter, the performance of CEM and PSM in preprocessing data from a non-
experimental database containing information on men diagnosed with intermediate-risk PCa 




5.2.1 Data source 
 
Data were abstracted from the Prostate Cancer Risk Stratification (ProCaRS) database. 
This database contains data on 7974 patients diagnosed with prostate cancer and treated with 
different forms of primary RT between 1994 and 2010 from four Canadian institutions in 
Toronto, Quebec City, Montreal and Vancouver.(144) Median follow-up was 79 months, and a 
total of 1442 (19%) patients developed biochemical failure. Details regarding ethics approval, 
database construction and quality assurance have been previously described.(20) 
 
5.2.2 Comparison one: BT and ADT versus EBRT and ADT 
 
The first comparison was based on a RCT performed by Morris and colleagues, which 
compared the rate of biochemical failure among men diagnosed with intermediate-risk PCa 
according to the National Comprehensive Network and treated with EBRT and either low-dose 
rate BT boost therapy and ADT (BT+ADT) or dose escalated EBRT and ADT (E+ADT).(167) 
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Patients from the ProCaRS database were included in the comparison if they met the PCa-
specific eligibility criteria specified by Morris et al., with two modifications. First, patients who 
received low-dose rate BT as a monotherapy and without EBRT were included in the BT+ADT. 
Second, a range for ADT duration (4 to 16 months) was allowed rather than that specified by 
Morris et al (12 months) to accommodate a greater number of patients for analysis, as few 
patients underwent approximately 12 months of ADT in both treatment groups. Second, 
instead of specific dose-escalation protocols as investigated by Morris et al, patients 
undergoing E+ADT with a dose of ≥74 Gy or BT with a dose of ≥144 Gy were eligible for 
comparison. The final sizes of the BT+ADT and E+ADT groups were 433 and 132, respectively. 
The patient selection process is outlined in Figure 5.1a. 
 
7974 Men registered in ProCaRS database 
2037 men with complete information on required fields (age at diagnosis, tumor 
characteristics at diagnosis, treatment information, biochemical failure information)  
1275 men who started adjuvant hormone therapy 2-12 months before primary 
radiation therapy and had between 4 and 16 months of adjuvant hormone therapy 
674 men diagnosed with intermediate-risk disease (NCCN category 3) 
132 men treated with E+ADT 
with total dose ≥7400 Gy  
433 men treated with BT+ADT 
with dose ≥14400 Gy 
 





5.2.3 Comparison two: EBRT with vs without ADT 
 
As shown in chapter four, issues of confounding arose when comparing BPFS between 
men diagnosed with intermediate-risk non-metastatic PCa and treated with BT or EBRT due to 
differences in the risk of extraprostatic extention as defined by baseline PSA, cTS, and GS. 
Confounding is also a concern when comparing the occurrence of oncological outcomes among 
men diagnosed with PCa and treated with RT alone or in combination with androgen 
deprivation therapy (ADT). Administration of ADT has demonstrated improvements in 
oncological outcomes attributed to a radiosensitization effect that improves response to RT 
while targeting occult micrometastases and extraprostatic extension.(173,174) However, since 
ADT leads to side effects and increases the risk of non-PCa death,(175) administration is 
reserved for those with higher PSA, Gleason score and clinical stage who are at an increased 
risk of biochemical failure, and PCa-specific death.  
The second treatment comparison was based on a RCT performed by Jones and 
colleagues, which sought to compare, among other outcomes, rate of biochemical failure 
among men diagnosed with localized PCa and treated with External Beam RT alone (EBRT) or in 
combination with short-term ADT (E+ADT).(91) Patients from the ProCaRS database were 
included in the comparison if they adhered to PCa-specific eligibility criteria as specified by 
Jones et al. This involved those with histologically confirmed prostate adenocarcinoma who had 
PSA levels of ≤20 ng/ml, a clinical T-stage ≤2, and without nodal or metastatic involvement at 
the time of diagnosis. Since the results of the study by Jones et al. suggested effect modification 
by risk-group, and the majority of men selected for this comparison (64.4%) from the ProCaRs 
database had intermediate-risk PCa, we further limited the source population to those 
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diagnosed with intermediate-risk PCa, using the definition provided by Jones et al. EBRT dose in 
both groups was limited to a total of ≥66 Gy, which slightly varies from the 66.6 Gy 
implemented by Jones and colleagues but was done to increase the number of participants for 
our comparison. Further, those who received 3-6 months of ADT before EBRT were included in 
the E+ADT group, which varies slightly from the four-month duration implemented by Jones et 
al. but was done for the purpose of increasing the sample size. The definition of biochemical 
failure was defined as an increase in the PSA level post-treatment of >2ng/ml above the 
nadir.(61) The final sample size included 126 and 579 men in the E+ADT and EBRT-only groups, 




Figure 5.1b Selection process for comparison two. 
 
 
5.2.4 Covariate selection 
 
We explored the potential for confounding through examining differences between 
treatment groups in distributions of baseline covariates that have demonstrated a prognostic 
role in relation to the rate of biochemical failure in previous literature.(19) Covariates included 
tumor characteristics (i.e. pre-biopsy PSA level, clinical T stage, and Gleason score), EBRT dose 
and treatment start date. Age was not included as a covariate since it has not demonstrated a 
consistent association with rate of biochemical failure in previous literature,(176,177) and did 
not demonstrate a notable association with the rate of biochemical failure in either 
comparison. Further, age was strongly associated with treatment choice, which would bias 
effect estimates if adjusted for.(168) 
 
7974 Men registered in ProCaRS database 
2568 men with complete information on required fields (age at diagnosis, tumor 
characteristics at diagnosis, treatment information, biochemical failure information)  
1764 men with baseline PSA ≤20 ng/ml and clinical T stage ≤2c 
126 men diagnosed with intermediate-
risk PCa and treated with 3-6 months of 
adjuvant hormone therapy 
1379 men treated with EBRT with total dose ≥6600 Gy 
579 men diagnosed with intermediate-
risk PCa and treated without adjuvant 
hormone therapy 
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5.2.5 Propensity score matching 
 
The PS model was built according to the systematic approach given in chapter four using the 
set of balance diagnostics recommended in chapter three to guide development and 
evaluation. Briefly, the PS model was a logistic model with prognostic characteristics as 
independent variables and type of treatment received as a binary dependent variable.(168) We 
explored the possibility of interactions and non-linearity for baseline covariates when 
developing the PS model, as appropriate specification of interaction and non-linear terms has 
demonstrated ability to achieve greater balance in baseline covariates between treatment 
groups.(152,178) Locally weighted scatterplot smoothers were used to assess for departures 
from linearity in the relationship between continuous predictors and the log odds of the 
probability for receiving E+ADT. Improvements in the model fit were assessed using the 
likelihood ratio test and pseudo-R2. Baseline PSA was modeled as a restricted cubic spline with 
four knots, treatment start year was treated as a discrete variable with 2-year categories, and 
an interaction term between baseline PSA and Gleason score was added, as the model 
specifications improved the predictive value. The Hosmer-Lemeshow goodness-of-fit statistic 
was examined to test for model adequacy. Further, a plot of DFBETA statistics revealed one 
outlier wherein a subject received E+ADT instead of BT+ADT despite a very low PSA, clinical T-
stage, and Gleason score. This patient was retained, as he did not have any relative or absolute 
contraindications to receiving E+ADT. The MatchIt package in R was used to match participants 
between treatment groups on the PS using progressively smaller calipers to identify the optimal 
balance to sample size trade-off.(146) Specifically, ratios of 1:3 and 1:4 were used for 
comparison one and two, respectively, given the ratio of index to reference observations 
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available. We also examined matching ratios of 1:1 and 1:2 but did not find any meaningful 
difference in balance or effect estimates other than decreased precision compared to 1:3 and 
1:4 matching ratios. Caliper widths included a range of 0.5 to 0.005 standard deviations of the 
logit of the PS (S Tables 5.1a and 5.1b). Nearest-neighbour matching was used without 
replacement. Compared to other matching approaches, nearest-neighbor matching with 
calipers and without replacement has been found to be less computationally burdensome and 
produce matches resulting in similar or increased balance, and similar or decreased bias and 
variance.(179)  
 
5.2.6 Coarsened exact matching 
 
Coarsening of baseline covariates used in CEM were informed by previous evidence 
surrounding the risk of PCa-specific death over 15 years after diagnosis.(180) In patients with a 
PSA of <4, 4 to 10, 10.1 to 20 and 20.1 to 50 ng/ml, the risk of PCa-specific death has been 
estimated to be 4%, 9%, 11%, and 22%, respectively.(180) Moreover, risk evaluation used to 
guide treatment decisions heavily relies on such thresholds.(19) As such, progressive coarsening 
for PSA was based on these ranges. Clinical stage, as determined through physical examination 
of the prostate or imaging, is an ordinal characteristic that takes on values of stages 1-4 with 
substages ‘a’ through ‘d’. Stages 1a-1c at diagnosis are assigned when there is no palpable 
tumor detected through digital rectal examination. Along with palpable tumors that occupy one 
side of the prostate (i.e., T2a and T2b, depending on year of classification), the risk of PCa-
specific death over 15 years has been estimated to be between 6% and 7%, so were collapsed 
into one category.(180) In contrast, patients with bilateral disease not felt to extend outside the 
prostate upon digital rectal examination (T2b depending on year of classification and T2c) have 
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been estimated to have approximately twice the risk of PCa-specific death over 15 years post-
diagnosis as those with unilateral disease, so formed another category for matching. Gleason 
score was divided into 6 (3+3), 7 (3+4) and 7 (4+3), as these values are associated with notable 
differences in prognosis. 
Patients were matched directly on ordinal covariates (i.e., Gleason score, and collapsed 
categories of clinical T-stage) and progressively coarsened continuous variables (i.e., PSA, year 
of RT, EBRT dose (if applicable)). Progressive coarsening for year of treatment was 
accomplished by dividing the range of values approximately evenly (i.e., halves, thirds, etc.)  in 
the E+ADT group. EBRT dose was split into low (≥6600 Gy and <7300 Gy) and high (≥7300 Gy to 
<7980 Gy) dosage. Coarsening ranges are presented in S Tables 5.2a and 5.2b. 
 
5.2.7 Balance diagnostics 
 
 Many balance diagnostics exist and have been rigorously assessed using various 
empirical and simulation datasets that represent a broad range of data characteristics. We 
chose three balance measures that consider different data characteristics in order to monitor 
improvements in balance when further restricting matching strategies (i.e., using finer ranges 
for continuous variables in CEM and smaller caliper widths in PSM), while enabling a 
comprehensive comparison of improvements in balance between PSM and CEM. The 
standardized mean difference (SMD) in proportion of observations having high-intermediate 
risk versus low-intermediate risk PCa as defined by the ProCaRS system was used as a 
prognostic score-based balance measure.(19) The ProCaRS risk-groups capture imbalance in 
combinations of specific values for baseline covariates to the extent that each is associated with 
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variation in the rate of biochemical failure. Stuart et al. have demonstrated that a prognostic 
score-based imbalance measure strongly correlated with bias in effect estimates.(156) Since 
our prognostic score-based balance measure only involved two risk-groups, it was limited in 
capturing subtle differences in individual variables. As such, we also examined the absolute 
SMD for individual variables to improve sensitivity in identifying violations of balance in 
individual variables and the average absolute SMD for baseline covariates to monitor average 
reduction in absolute SMD when restricting matching strategies to improve balance. Both the 
absolute and average absolute SMD for baseline covariates have demonstrated a strong 
correlation with bias in effect estimates in simulation studies.(156,160,161) In addition to these 
three measures, we also examined the overlap in continuous baseline covariates through 
overlying density plots and variance ratios. 
 
5.2.8 Descriptive statistics and multivariable regression analysis 
 
 All statistical analyses were performed using RStudio version 3.6.0.(169) Descriptive 
statistics were calculated for each treatment group before and after matching. The median and 
interquartile range are presented for continuous variables and proportions for categorical 
variables. Cox proportional-hazards regression analyses for estimating the effect of treatment 
group on the hazard of biochemical failure were performed using the Survival package.(181) 
Log-minus-log survival plots and scaled Schoenfeld residuals were examined for violations of 
proportional hazards, which, when present, were handled by modeling variables as a function 
of time. Improvements in model fit were examined through informally comparing the model log 
likelihoods after incorporating higher order terms and transformations for continuous 
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covariates. Examination of a plot of DBETA statistics did not identify any influential 
observations. Hazard ratios and 95% confidence intervals were estimated from unmatched data 
both without and with adjustment for the natural logarithm of PSA, clinical stage, Gleason 
score, RT start year, and EBRT dose (if applicable). For matched data, we employed Cox models 
clustered by the matched sets with associated weights to account for variable matching ratios, 
using robust variance estimators to generate confidence intervals.(181,182) For the CEM 
strategies, the continuous covariates were included in the model to control for possible residual 




5.3.1 Comparison one: BT+ADT versus E+ADT 
 
5.3.1.1 Descriptive statistics 
 Descriptive statistics for the unmatched treatment groups in comparison one are 
reported in Table 5.1a. Men treated with BT+ADT were, on average, younger (median age of 68 
vs 72 years, respectively) and were treated at earlier dates than men in the E+ADT group 
(median treatment start year of 2002 vs 2003, respectively). Tumor characteristics were 
generally less advanced in the BT+ADT group than in the E+ADT group (median PSA: 7.5 vs 9.0 
ng/ml, respectively; percentage of Gleason score 7 (4+3): 13% vs 34%) other than clinical stage 
wherein a greater proportion of BT+ADT had clinical T stage of T2b-c (14% vs 8%, respectively). 
This paralleled the smaller percentage of BT+ADT occupying the high-intermediate risk strata 
(7% vs 25%, respectively). Finally, the median duration of ADT was similar between groups (6.0 
vs 5.4 months).  
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Table 5.1a Descriptive statistics for comparison one 
 BT+ADT (n=433) E+ADT (n=132) SMD Variance 
Ratio 
Age   
Median 68 72 0.7644 0.55 
IQR 63, 72 69, 75   
Clinical T-Stage   
T1a-2a 373 86.14% 122 92.42% 0.2041  
T2b-c 60 13.86% 10 7.58%   
PSA (ng/ml)   
Median 7.60 9.02 0.3468 0.92 
IQR 5.70, 10.50 5.88, 12.60   
Gleason Grade   
1 126 29.10% 23 17.42% 0.2790  
2 249 57.51% 64 48.48% 0.1815  
3 58 13.39% 45 34.09% 0.5014  
RT Start Year   
Median 2002 2003 0.3029 0.67 
IQR 2001, 2004 2002, 2004   
ADT Duration (Months)   
Median 5.98 5.45 0.1285 2.84 
IQR 5.55, 6.81 4.82, 8.46   
PROCARS Risk Groups   
Low-intermediate 404 93.30% 99 75% 0.5177  
High-intermediate 29 6.70% 33 25%   
 
5.3.1.2 Performance of matching strategies  
The number of patients and events retained for each CEM and PSM strategy were 
examined in comparison one and are presented in S Tables 5.1a and 5.3a, respectively. PSM 
strategy 10 and CEM strategy eight led to optimal balance to sample size trade-off so were used 





Figure 5.2a Balance achieved with each PSM strategy by percent of data retained for comparison one.  















































































































Figure 5.2b Balance achieved with each CEM strategy by percent of data retained for comparison one.  
*The red dot indicates the chosen matching strategy 
 
 Median values for continuous covariates and proportions for categorical covariates 
according to matching strategy are presented in S Figures 5.1a and 5.1b. As matching 
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E+ADT until a certain point wherein characteristics in both groups tended toward those of the 
BT+ADT group. In the matching strategy chosen, characteristics for both groups represented an 
average of both groups, as would be expected in areas of common support. 
 Density plots for continuous covariates before and after matching are presented in S 
Figures 5.2a and 5.2b. Overlap in treatment start date and baseline ln(PSA) improved after both 
matching strategies.  
Descriptive statistics for the matched groups from the selected PSM and CEM strategies 
are presented in Table 5.2a. The distribution of baseline covariate values in the matched 
samples represents an average of the distribution of covariates from both groups.  
Table 5.2a Descriptive statistics for PSM strategy 10 and CEM strategy 8 in comparison one 
 PSM 10 CEM 8 
 BT+ADT (n=248) E+ADT (n=109) BT+ADT (n=276) E+ADT (n=96) 
Age (years)   
Median 69 72 69.5 72 
IQR 64, 72 69, 75 64, 72.25 69, 75 
Clinical T-Stage   
T1a-c 231 93.12% 102 93.58% 264 95.83% 92 95.83% 
T2b-c 17 6.88% 7 6.42% 12 4.17% 4 4.17% 
PSA (ng/ml)   
Median 7.60 8.06 7.95 8.47 
IQR 5.65, 10.60 5.63, 10.70 6.08, 11.00 5.72, 11.78 
Gleason Grade   
1 52 21.10% 23 21.10% 63 22.92% 22 22.92% 
2 119 47.86% 52 47.71% 152 55.21% 53 55.21% 
3 77 31.04% 34 31.19% 60 21.88% 21 21.88% 
RT Start Year   
Median 2003 2003 2003.5 2003.5 
IQR 2002, 2004 2002, 2004 2002, 2005 2002, 2005 
ADT Duration (Months)   
Median 5.98 5.49 5.95 5.67 
IQR 5.55, 6.78 4.80, 8.08 5.48, 6.83 4.93, 8.51 
PROCARS Risk Groups   
Low-intermediate 26 10.55% 13 11.93% 236 85.42% 92.89 85.42% 
 79 
High-intermediate 222 89.45% 96 88.07% 40 14.58% 3.11 14.58% 
 
 
 SMDs of individual covariates after PSM and CEM relative to the source population are 
presented in Figure 5.3. PSM and CEM improved balance in the absolute SMD relative to the 
unmatched sample. CEM achieved similar or more balance in the absolute SMD relative to PSM. 
 
Figure 5.3 Love plot of the absolute SMD for individual baseline covariates before 
matching and after PSM and CEM in comparison one. 
 
The effect estimates are presented in Table 5.3a. For the benchmark RCT hazard ratio 
estimate (95% confidence interval) of 2.04 [1.25, 3.33], the corresponding unadjusted effect 
hazard-ratio estimate (95% CI) was 6.55 [3.82, 11.26], while adjusting for relevant baseline 
covariates, the hazard-ratio estimate (95% CI) decreased to 4.48 [2.44, 8.22]. The unadjusted 
and multivariable adjusted hazard-ratio estimates (95% CI) after PSM were 4.06 [1.98, 8.11] and 
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3.84 [1.91, 8.71], respectively, while those after CEM were 4.04 [1.88, 8.66] and 3.84 [1.77, 
8.34], respectively. Other candidate matching strategies for both PSM and CEM that 
demonstrated similar improvements in imbalance led to similar point estimates and confidence 
intervals (Table 5.3a). 
Table 5.3a Effect estimates obtained from unmatched and matched samples from comparison 
















RCT 2.17 1.33 3.45 2.04 1.25 3.33 
UNM 6.55 3.82 11.26 4.48 2.44 8.22 
CEM 6 3.79 1.78 8.08 3.67 1.68 8.02 
CEM 8 4.04 1.88 8.66 3.84 1.77 8.34 
CEM 9 2.81 1.17 6.81 2.74 1.12 6.73 
PSM 9 4.25 2.23 8.08 3.76 1.94 7.27 
PSM 10 4.06 1.98 8.11 3.84 1.91 7.71 
PSM 11 3.86 1.85 8.05 3.87 1.84 8.15 
 
 
5.3.2 Comparison two: EBRT versus E+ADT 
 
5.3.2.1 Descriptive Statistics  
 Descriptive statistics for unmatched treatment groups in analysis two are reported in 
Table 5.1b. Treatment groups were similar (SMD<0.1) with respect to age, PSA, and proportion 
of low- vs high-intermediate risk-group status. The E+ADT group had a slightly greater 
proportion of men diagnosed with clinical T1a-2a disease than the EBRT group. Those in the 
E+ADT group also had a greater proportion of Gleason sum 7 (3+4) and 7 (4+3) disease and 
received higher doses of EBRT, on average. Men from the E+ADT group also received 
treatment, on average, later than those from the EBRT group in calendar time. 
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Table 5.1b Descriptive statistics for PSM strategy 4 and CEM strategy 7 in comparison two 
 PSM 6 CEM 7 
 E+ADT (n=126) EBRT (n=347) E+ADT (n=118) BT+ADT (n=377) 
Age (years)   
Median 72 72 72 72 
IQR 68.25, 75 68, 75 69, 75 66, 74 
Clinical T-Stage   
T1a-c 109 86.51% 298 85.91% 105 88.98% 335 88.98% 
T2b-c 17 13.49% 49 14.09% 13 11.02% 42 11.02% 
PSA (ng/ml)   
Median 8.75 8.47 8.81 8.50 
IQR 5.71, 12.46 5.87, 12.05 5.75, 12.15 6.10, 12.30 
Gleason Grade   
1 23 18.25% 68 19.64% 22 18.64% 70 18.64% 
2 67 53.18% 179 51.46% 66 55.93% 211 55.93% 
3 36 28.57% 100 28.90% 30 25.42% 96 25.42% 
RT Start Year   
Median 2001 2001 2001 2001 
IQR 2000, 2004 2000, 2004 2000, 2004 2000, 2004 
EBRT Dose (Gy)   
Median 7560 7560 7560 7560 
IQR 7400, 7980 7400, 7980 7400, 7980 7400, 7980 
PROCARS Risk Groups   
Low-intermediate 88 69.84% 252 72.75% 82 69.49% 258 68.40% 
High-intermediate 38 30.16% 95 27.25% 36 30.51% 119 31.60% 
 
5.3.2.2 Performance of matching strategies  
Data characteristics for PSM and CEM strategies examined in comparison two are 
presented in S Tables 5.1b and 5.3b, respectively. PSM strategy six and CEM strategy seven led 
to optimal balance to sample size trade-off so were used for further analysis. Figures 5.4a and 
5.4b show the selection processes for PSM and CEM, respectively, with the red data points 
representing the matching strategies that led to optimal balance to sample size trade-off. Sixty-
eight percent and 70% of the source population were retained through PSM and CEM, 
respectively. The associated mean SMDs were 0.034 and 0.015, while the risk-group SMDs were 
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0.022 and 0.024, respectively. Both strategies maintained SMD for all individual covariates 




Figure 5.4a Balance achieved with each PSM strategy by percent of data retained for comparison two. 

















































































































Figure 5.4b Balance achieved with each CEM strategy by percent of data retained for comparison two.  
*The red dot indicates the chosen matching strategy 
 
Descriptive statistics for the matched groups from the selected CEM and PSM strategies 
are presented in Table 5.2b. The distribution of baseline covariate values in the matched 
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Table 5.2b Descriptive statistics for PSM strategy 4 and CEM strategy 7 in comparison two 
 PSM 6 CEM 7 
 E+ADT (n=126) EBRT (n=347) E+ADT (n=118) BT+ADT (n=377) 
Age (years)   
Median 72 72 72 72 
IQR 68.25, 75 68, 75 69, 75 66, 74 
Clinical T-Stage   
T1a-c 109 86.51% 298 85.91% 105 88.98% 335 88.98% 
T2b-c 17 13.49% 49 14.09% 13 11.02% 42 11.02% 
PSA (ng/ml)   
Median 8.75 8.47 8.81 8.50 
IQR 5.71, 12.46 5.87, 12.05 5.75, 12.15 6.10, 12.30 
Gleason Grade   
1 23 18.25% 68 19.64% 22 18.64% 70 18.64% 
2 67 53.18% 179 51.46% 66 55.93% 211 55.93% 
3 36 28.57% 100 28.90% 30 25.42% 96 25.42% 
RT Start Year   
Median 2001 2001 2001 2001 
IQR 2000, 2004 2000, 2004 2000, 2004 2000, 2004 
EBRT Dose (Gy)   
Median 7560 7560 7560 7560 
IQR 7400, 7980 7400, 7980 7400, 7980 7400, 7980 
PROCARS Risk Groups   
Low-intermediate 88 69.84% 252 72.75% 82 69.49% 258 68.40% 
High-intermediate 38 30.16% 95 27.25% 36 30.51% 119 31.60% 
 
Median values for continuous covariates and proportions for categorical covariates 
according to matching strategy are presented in S Figures 5.3a and 5.3b. As matching 
approaches became stricter, the EBRT group characteristics tended toward those of the E+ADT 
until a certain point wherein characteristics in both groups tended toward those of the EBRT 
group. In the matching strategy chosen, characteristics for both groups represented an average 
of both groups, as would be expected in areas of common support. 
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Density plots for continuous covariates before and after matching are presented in S 
Figures 5.4a and 5.4b. Similar to comparison one, overlap in treatment start date and baseline 
ln(PSA) improved after both matching strategies compared to the unmatched sample.  
SMDs of individual covariates after PSM and CEM relative to the unmatched sample are 
presented in Figure 5.5. Both matching strategies improved balance in the absolute SMD in all 
covariates relative to the unmatched sample except baseline ln(PSA), as this variables was 
already balanced between groups.  
 
Figure 5.5 Love plot of the absolute SMD for individual baseline covariates before 
matching and after PSM and CEM in comparison two. 
 
The effect estimates are presented in Table 5.3b. Compared to the benchmark RCT 
hazard ratio (95% CI) of 1.79 [1.45, 2.21], the unadjusted effect estimate (95% CI) was 1.40 
[0.99, 1.98]. After adjusting for relevant baseline covariates, the hazard ratio estimate (95% CI) 
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increased to 1.52 [1.06, 2.16]. The unadjusted and multivariable adjusted hazard-ratio 
estimates (95% CI) after PSM were 1.39 [0.97, 1.99] and 1.44 [1.00, 2.05]. CEM provided similar 
effect estimates (1.53 [0.95, 2.46] without adjustment and 1.55 [0.98, 2.45] after multivariable 
adjustment). Other candidate matching strategies for both PSM and CEM that demonstrated 
similar improvements in imbalance led to similar point estimates and confidence intervals 
(Table 5.3b). 
Table 5.3b Effect estimates obtained from unmatched and matched samples from comparison 
















RCT - - - 1.79 1.45 2.21 
UNM 1.40 0.99 1.98 1.52 1.06 2.16 
CEM 7 1.53 0.95 2.46 1.55 0.98 2.45 
CEM 8 1.49 0.98 2.26 1.52 1.00 2.29 
CEM 9 1.48 0.93 2.36 1.52 0.92 2.43 
PSM 4 1.43 1.01 2.01 1.47 1.04 2.07 
PSM 5 1.43 1.00 2.04 1.46 1.02 2.08 




 The purpose of this study was to compare the performance of two popular data-
preprocessing techniques in the context of non-experimental datasets, using two examples 
from PCa CER. Balance in the distributions of individual variables, as measured by SMD, was 
improved with both PSM and CEM. CEM generally led to smaller SMDs for individual covariates 
and overall average SMD when compared with PSM, with similar proportions of retention of 
observations from the original dataset. Furthermore, the risk-group SMD, which reflects 
imbalance in prognostic score between treatment groups was improved through both PSM and 
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CEM, but to a greater extent after CEM. Likewise, the variance ratio for continuous covariates 
was closer to one after both matching strategies but more so after CEM than PSM for baseline 
PSA and treatment start date; however, PSM led to a variance-variance ratio closer to one for 
radiation treatment dosing between treatment groups. These findings are consistent with other 
studies wherein large improvements in balance were observed after CEM compared to PSM 
using balance diagnostics based on the comparison of multivariable distributions between 
treatment groups.(147,148) 
 In the first comparison, the rate of biochemical progression was elevated in the E+ADT 
compared with the BT+ADT group. Some of the difference in the rate of biochemical 
progression between treatment groups can be attributed to differences in the risk of 
extraprostatic extension, which is reflected in the baseline measures of PSA, clinical stage, and 
Gleason sum in addition to changing clinical practices and technology that occur overtime, 
which are reflected, in part, by the calendar year of treatment. After adjusting for such 
variables, the hazard ratio was attenuated (6.55 vs 4.48). The adjusted effect estimate is more 
consistent with that of the benchmark RCT (2.04). After both PSM and CEM, however, the 
effect estimate after multivariable modeling was, on average, closer to that of the benchmark 
RCT (3.84 and 3.84, respectively). Attenuation of the effect estimate after matching might be 
due to the limitations of multivariable regression modeling to adequately control for 
confounding. To clarify, appropriate model specification would require adequate 
representation of the functional forms of the relations between the study outcome and the 
treatment and confounders at issue (which may necessitate inclusion of polynomial terms for 
continuous characteristics), as well as adequate inclusion of the requisite – and possibly multi-
 88 
way – interaction terms between the independent variables. However, these relations do not 
necessarily operate according to such specifications. Furthermore, accurate modelling of effect 
estimates rests on the assumption of positivity, with even small violations of which potentially 
resulting in biased effect estimates.(183)  
Even without further adjustment for confounding, matching led to a stronger 
attenuation in the effect estimate than multivariable matching (4.06 and 4.04 for PSM and 
CEM, respectively, versus 4.48 after multivariable modeling alone) that was closer to the 
benchmark RCT. This might demonstrate the bias reduction potential offered through PSM and 
CEM even without further multivariable adjustment. However, the further attenuation in the 
effect estimate afforded through multivariable adjustment after matching demonstrates the 
remaining confounding not entirely managed by through matching strategies performed. 
In the second comparison, the rate of biochemical progression was elevated in the EBRT 
compared to the E+ADT group; however, the difference was likely underestimated since, as 
mentioned in the background, ADT is generally reserved for those with a greater risk of 
extraprostatic extension. This is reflected in the differences in baseline characteristics between 
treatment groups wherein those undergoing E+ADT had, on average, worse prognosis than 
those in the EBRT group. However, such differences in prognosis were not as substantial as 
differences in prognosis between treatment groups in the first comparison, as demonstrated by 
the smaller risk-group SMD in comparison two relative to one (0.075 versus 0.52, respectively). 
Multivariable adjustment led to an increased effect estimate (1.52 versus 1.40) after adjusting 
for potential confounding variables. The relative difference in unadjusted and adjusted effect 
estimate compared with the first comparison was much smaller. This is likely attributable to the 
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greater balance observed between treatment groups in comparison two relative to that in 
comparison one. This notion is further supported in that matching did not substantially change 
effect estimates (1.44 and 1.55 after PSM and CEM, respectively).  
 An alternative explanation for the observed differences in the effect estimates might be 
the differences in treatments implemented in the randomized trial relative to those 
administered in the ProCaRS database. Since BT monotherapy and EBRT without dose 
escalation are likely to have different impacts on the rate of biochemical failure compared to 
EBRT with BT boost and EBRT with dose-escalation, the ASCENDE-trial can serve only as a loose 
guideline in interpreting effect estimates rather than a gold standard. Another explanation 
could be that each approach estimates a different parameter. Specifically, multivariable 
regression modeling estimates – albeit approximately – the average treatment effect in the 
study population. In contrast, PSM and CEM provide for estimates of the average treatment 
effect among the index-treatment group (i.e., E+ADT), which has been termed the average 
treatment effect among the treated. In our case, however, since some observations from the 
index-treatment group were dropped after PSM and CEM, we estimated the average treatment 
effect among the treated who remained after matching, which has been termed by Iacus and 
colleagues as the feasible sample average treatment effect among the treated.(159) Random 
variation of the hazards ratio might also explain the findings, at least partly. However, effect 
estimates drawn from several candidate PSM and CEM strategies consistently estimated effects 
more in line with the benchmark RCT in comparison one where imbalance was substantial; 
whereas effect estimates provided through several candidate PSM and CEM strategies 
consistently estimated effects similar to that provided through multivariable modeling where 
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imbalance was not as substantial. The comparison of results from the benchmark RCTs with 
those obtained after matching to support trends in bias reduction is limited since characteristics 
of the treatment groups and treatment approaches for each comparison varied notably from 
the chosen benchmark RCT. 
We found that both CEM and PSM led to matched samples with average values of 
characteristics falling in a range of observed values of characteristics in each treatment group. 
This is expected since it represents areas of common support. This is also favorable since results 
are more ‘generalizable’ to patient groups with characteristics that are amenable for either 
treatment under comparison. In contrast, Fullerton et al. found that CEM led to matched 
samples that differed greatly from the original population and either treatment group in their 
baseline characteristics.(147) This seeming discrepancy is likely explained by the difference in 
dimensionality between datasets used for matching. The covariate sets Fullerton et al. used to 
match between comparison groups involved over 80 variables, whereas we only used matching 
on four and five covariates. This explanation is supported by findings from Ripollone et al., who 
reported that smaller covariate sets of 8 covariates retained a substantially greater proportion 
of the original population compared to larger covariate sets with up to 119 covariates (32.5% vs 
3.6%, respectively).(148)  
The precision of effect estimates did not differ notably between PSM and for CEM. 
Although Fullerton et al. and Ripollone et al. found that greater precision was observed for PSM 
than for CEM in high-dimensional datasets, differences attenuated as the number of covariates 
decreased.(147,148) Since our datasets included a small number of covariates, similarity in 
precision achieved after PSM and CEM is to be expected. 
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 The PSM paradox, as demonstrated by King and Nielsen,(136) became apparent when 
restricting matches to exceedingly smaller caliper ranges. In particular, measures of imbalance 
became very sporadic, increasing and decreasing with progressively smaller calipers ≤0.1 in 
analysis one and ≤0.2 in analysis two (Figures 5.2a and 5.4a). This could also be due to the fact 
that sample sizes of comparison groups became exceedingly smaller as caliper size 
progressively decreased. Austin noted that the standard deviation of SMD increases in smaller 
samples, so greater variation of SMD is expected with progressively smaller calipers.(152) This 
phenomenon was also observed in a study by Belitser et al., who found correlation of SMD with 
bias decreased in smaller sample sizes.(161) These findings have substantial implications for 
researchers who use standard caliper sizes instead of exploring progressively smaller caliper 
ranges to identify optimal balance before the PSM paradox kicks in or when estimation of 
balance becomes sporadic and unreliable. Thus, we recommend that analysts explore 
progressively smaller matching calipers when PSM in order to examine the trade-off between 
balance and sample size and identify a suitable matching strategy for their research purposes. 
 Our study had several strengths. First, we used a systematic approach to identifying an 
optimal matching strategy through identifying the ‘plateau’ in the association between balance 
and percentage of retention of the original study population with progressively stricter 
matching criteria (i.e., smaller caliper sizes in PSM and finer ranges in continuous variables in 
CEM). Second, we used matching ratios that retained a greater number of reference-treatment 
observations to enhance precision of the effect estimates after PSM. Third, we took advantage 
of a priori knowledge to inform our decisions on CEM cut-points for continuous variables rather 
than rely solely on quantile-based rules, as in previous studies.(145,147) This has the potential 
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to optimize the efficiency of matching strategies by reducing imbalance while retaining a 
greater part of the original sample. Finally, the use of effect estimates from real world evidence 
provided from RCTs performed in a similar era among patients with similar characteristics 




 In summary, both matching strategies appear to be effective in managing confounding. 
The use of multivariable adjustment should be used in conjunction with matching strategies, as 
shown here, has potential to control for residual confounding after matching. In contrast with 
recent reports, CEM appears to be a feasible strategy for pre-processing of non-experimental 
data with a relatively small number of covariates that can result in retention of a large 
proportion of the original study sample from which to generate effect estimates with 
reasonable precision and utility to inform clinical practice in the absence of RCTs. CEM also has 
potential to further improve balance in the multivariable distribution of baseline covariates 
between comparison groups, compared with PSM. 
 
5.6 Transition to Chapter Six 
 
 This chapter compared the performance of propensity score matching and coarsened 
exact matching in the ability to balance the multivariable distribution of baseline covariates per 
level of data retention using methods developed in chapter four. Two treatment comparisons 
of men diagnosed with PCa and treated with different combinations of RT and ADT in Canada 
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were used to compare these matching strategies. RCTs that compared similar groups of men 
who were similarly managed were used to further inform how changes in balance led to 
changes in effect estimates. The results from this comparison thus add to the real-world 
evidence on the performance of matching strategies and show the potential that matching can 
have in improving the validity of effect estimates in PCa comparative effectiveness research. As 
such, the methods developed and evaluated in chapters four and five were used in a 
comparison of the rate of MPFS between men diagnosed with unfavorable-risk non-metastatic 
PCa who were initially treated with either RT or RP in chapter seven.  
However, before chapter seven, a systematic review and meta-analysis of studies 
comparing the rate of CSS between men diagnosed with high-risk non-metastatic PCa who were 
initially treated with either RT or RP was performed in response to limitations in a previous 
meta-analysis on the topic and to provide context from the medical literature for the 
comparison done in chapter seven. Comparisons using records from men diagnosed with high-
risk non-metastatic PCa instead of unfavorable-risk (i.e., unfavorable-intermediate-, high- and 
very-risk) non-metastatic PCa is performed, as the term unfavorable-risk is a recent change in 
risk-stratification terminology.(19) Therefore, most studies with sufficient follow-up for CSS that 
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Identifying the optimal management of high-risk non-metastatic prostate cancer (PCa) is an 
important public health concern given the large burden of this disease. We performed a meta-
analysis of studies comparing PCa-specific mortality (CSM) and all-cause mortality (ACM) among 
men diagnosed with high-risk non-metastatic PCa who were treated with primary radiotherapy 
(RT) and radical prostatectomy (RP).  
Methods 
 
Medline and EMBASE were queried for articles between 2005 to 2020. After title and abstract 
screening, two authors independently reviewed full-text articles for inclusion. Data were 
abstracted and a modified version of the Newcastle-Ottawa Scale, involving a comprehensive 
list of confounding variables, was used to assess risk of bias. 
Results 
 
Fourteen studies involving 88,543 patients were included. No difference in adjusted CSM in RT 
relative to RP was shown (hazard ratio, 1.02 [95% confidence interval: 0.84, 1.25]). Increased 
CSM was found in a moderator analysis comparing external beam radiation therapy (EBRT) with 
RP (1.35 [1.10, 1.68]) whereas EBRT combined with brachytherapy (BT) versus RP showed lower 
CSM (0.68 [0.48, 0.95]). All studies demonstrated a high risk of bias, as none fully adjusted for 
all confounding variables. 
Conclusion 
 
We found no difference in CSM and ACM between men diagnosed with non-metastatic high-
risk PCa treated with RP or RT; however, this is likely explained by increased CSM in men 
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treated with EBRT and decreased CSM in men treated with EBRT+BT studies relative to RP. 
High-risk of bias in all studies identifies the need for better data collection and confounding 




6.1 Rationale and Objectives 
 
Prostate cancer (PCa) was the second most frequently diagnosed cancer and fifth 
leading cause of cancer death worldwide as of 2018.(3) High-risk PCa, as defined by a clinical 
stage ≥T3, Gleason score 8-10 or prostate-specific antigen >20ng/ml at the time of 
diagnosis,(184) accounts for approximately one quarter of all PCa diagnoses but was 
responsible for a disproportionately larger share of PCa-specific mortality (CSM).(185) Optimal 
selection and sequencing of therapy for high-risk non-metastatic PCa, such as the choice 
between radical prostatectomy (RP) and radical radiotherapy (RT), remains an area of intense 
academic and clinical debate.(108) Unfortunately, no RCTs on this topic have been completed 
due to low patient and provider equipoise surrounding RP and RT, especially in North 
America.(110)(111) As such, investigations comparing RP and RT outcomes have mostly been 
performed using non-randomized data. In the absence of RCTs, meta-analyses that summarize 
non-randomized data can inform treatment decisions for physicians and policymakers.  
Previous meta-analyses that have compared mortality outcomes between patients 
diagnosed with PCa and treated with RP or RT involved studies that compared older treatment 
approaches, which greatly differ from current standards of care.(186) Publications included in 
these meta-analyses have since been updated to include longer follow-up periods of more 
contemporary RT approaches such as dose-escalation protocols for external beam radiation 
therapy (EBRT), use of brachytherapy boost (BT) and adjuvant androgen deprivation therapy 
(ADT),(101,120,187,188) which may lead to better oncological outcomes for men diagnosed 
with high-risk non-metastatic PCa.(91,167,189) Although a more recent meta-analyses has been 
conducted,(190) numerous errors were made, limiting the utility of the aggregated effect 
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estimates for use in clinical practice. For instance, multiple effect estimates were generated 
from overlapping data,(99,120,191–196) leading to some patient data overinfluencing 
aggregate effect estimates as well as inclusion of a study investigating low-risk PCa.(187) 
Moreover, the authors aggregated studies involving patients diagnosed with non-metastatic 
and nodal metastatic high-risk PCa,(193) which have heterogenous disease trajectories and 
ultimately call for different management approaches that are not comparable.(21) 
The objective of this study was to compare the rates of CSM and ACM between men 





6.2.1 Research question 
 
The primary and secondary objectives of the study were to summarize the relative CSM 
and ACM, respectively, of patients diagnosed with non-metastatic high-risk PCa treated 
primarily with either RP or RT. 
Common endpoints used to compare treatment effectiveness in PCa also have potential 
for bias. These include BFFS, metastatic progression-free survival (MPFS), CSS and OS. The 
definition of biochemical failure among patients treated with RP and RT differ. Since RP 
removes the whole prostate gland, it is anticipated that the prostate specific biomarker (used 
to define biochemical failure) maintain a non-significant value of <0.2ng/ml.(121,122) Since RT 
does not remove the gland, it is anticipated that some prostate specific biomarker remains.(61) 
The biochemical failure definition post-RP intended to indicate cure whereas the definition 
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post-RT is sensitive and specific for future clinical outcomes of interest (e.g. distant failure, PSA 
>25 ng/ml, etc.).(123,124) These definitions represent different disease kinetics and outcomes 
and should not be compared in the context of comparative effectiveness research. Evidence of 
metastasis depends on the presence of prompts to image such as biochemical failure and 
symptoms.  Prompts may differ depending on whether the patient underwent RP or RT and the 
frequency of follow-up, which is dependent on characteristics of the patient, physician, and 
treatment centre among other factors. Finally, PCa-specific mortality as ascertained by death 
certificates is not immune to bias. Death is sometimes misattributed to PCa among PCa patients 
who die of other causes. This misattribution bias is more likely to occur among those with 
multiple comorbidities, as deciphering cause of death among multiple causes can be difficult. 
Since RT patients are more likely to have multiple comorbidities, this would negatively impact 
survival outcomes when compared with patients undergoing RP independent of treatment 
status. OS poses little concern for measurement bias, as causes do not have to be ascertained. 
 
6.2.2 Protocol and search strategy 
 
The systematic review was conducted in accordance with the PRISMA guidelines.(197) 
The review protocol has been registered with PROSPERO (registration number: 
CRD42020150710). The search strategy is provided in Appendix E1. Studies were included in our 
analysis if they were published after 2005 to limit attention to analyses of more contemporary 
treatment periods up to February 11, 2020. Only full-text articles published in English in a peer-
reviewed journal were considered.  
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We included only cohort studies in our review since case-control studies typically do not 
evaluate hazard ratios. Furthermore, previous RCTs were excluded since, due to insufficient 
numbers of men diagnosed with nonmetastatic high-risk PCa, hazard ratios for this risk-group 
were not provided.(198) Editorials, letters to the editor, commentaries, guidelines and review 
articles were also excluded. 
We included studies that reported on men of any age diagnosed with non-metastatic 
high-risk PCa, according to the National Comprehensive Cancer Network (clinical stage ≥ T3 or 
Gleason score 8-10 or prostate specific antigen > 20 ng/ml),(184) or D’Amico criteria (clinical 
stage ≥ T2c or Gleason score 8-10 or prostate specific antigen > 20 ng/ml)(25) who were treated 
with either primary RP or RT. All common forms of RP (e.g., open retropubic, laparoscopic, and 
robotic) and RT (e.g., conformal external beam, intensity-modulated, brachytherapy or 
combination of radiotherapy modalities with curative intent) were considered. Studies 
assessing adjuvant or salvage therapies as the primary objective were excluded. We included 
only studies that provided a hazard ratio for CSM or ACM, both having managed confounding 
(i.e., through prevention or adjustment). Studies reporting on surrogate outcome measures 
such as biochemical progression were excluded, since definitions for RP and RT differ.  
 
6.2.3 Article review 
 
The first phase of the project involved title and abstract review by DG to discard non-
relevant citations and duplications. Full-text reviews of remaining studies were examined in the 
second phase by DG and HC to determine eligibility for inclusion based on pre-determined 
criteria. Afterward, DG and HC independently reviewed the records, and GBR settled 
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discrepancies on inclusion/exclusion of certain records. Where more than one publication 
existed using the same patient population, the most relevant, updated, and complete 
publication was selected. A diagram describing the study flow is outlined in Figure 6.1.  
 
Figure 6.1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow 
diagram outlining search strategy and final included and excluded studies. 
 
6.2.4 Data extraction and risk of bias assessment 
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A data extraction form was completed for each study as outlined in Appendix E2. We 
used a modified version of the Newcastle Ottawa Scale to include a comprehensive list of items 
identifying confounding variables (see Appendix E3). Confounding variables included those 
relating to tumor characteristics (baseline PSA, Gleason score, and clinical stage), age, 
comorbidity status, year of diagnosis or treatment, study center (if multiple), and at least one 
demographic characteristic (e.g., education, income, rural or urban residence). This list was 
reviewed and approved by both a radiation oncologist (GR) and uro-oncologist (JC).  
 
6.2.5 Publication bias 
 
 We assessed publication bias using funnel plots and the Egger test. Hazard ratios from 
included studies were plotted as a function of their standard error in relation to the aggregate 
effect estimate generated through random-effects models. Residual values were also estimated 
using mixed-effects models to account for heterogeneity due to moderator variables (RT 
approach for CSM and ACM, and age for ACM) in order to improve interpretation of funnel 
plots for the assessment of publication bias. 
 
6.2.6 Assessment of heterogeneity 
 
The Q-test was performed to identify significant heterogeneity in treatment effect 
estimates, using the Dersimonian-Laird method, and quantified through the I2 statistic.(199) 
 
6.2.7 Statistical analysis 
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 General study information, PCa treatment and endpoint information, and 
methodological information were categorized into tables using frequency or proportions for 
categorical variables, medians or means for continuous variables, and descriptive terms for 
other variables where appropriate.  
The meta-analysis was performed in R (x64, version 3.3.2; R Foundation for Statistical 
Computing) with the “metafor” package (version 1.9-9).(200) The primary meta-analysis with 
CSM as the outcome and initial treatment received (i.e., RP or RT) as the only independent 
variable was carried out using inverse variance-weighted random effects models. We then 
performed a series of univariable meta-regressions to explore sources of heterogeneity. Input 
variables included treatment era (examined as a binary variable with values of 1 and 0 for 
values above and below the median year of diagnosis, respectively), approach to RT (external 
beam radiation therapy with or without brachytherapy boost), length of follow-up (examined as 
a binary variable with values of 1 and 0 for values above and below the median, respectively), 
geographical location (United States versus other) and age (examined as a binary variable with 
values of 1 and 0 for values above and below the median, respectively). Insufficient data were 
available to explore the effect of RT dose, RP approach (i.e., open, laparoscopic, robotic), 
proportion receiving systemic therapy (i.e., androgen deprivation therapy, chemotherapy, and 
adjuvant RT), and type of EBRT (i.e., 3D conformal, IMRT, etc.). All statistical tests were two-





 Fourteen studies involving 89,167 total patients were identified for inclusion. The article 
selection flowchart is outlined in Figure 6.1.  
 
6.3.1 Study characteristics 
 
Table 6.1 shows characteristics for individual studies. Four studies compared treatment 
groups from a single institution, another four studies compared groups from different 
institutions, another four studies used national registries to compare treatment groups and two 
studies made comparisons across multiple institutions. Patient characteristics varied across 
studies due to variations in inclusion and exclusion criteria. In general, RT patients were, on 
average, older, had a greater number of comorbidities and poorer prognostic characteristics. 
Median follow-up varied substantially between studies and between treatment groups. 
Treatment details were scarcely reported for the RP group, while details regarding RT dose, 
proportion receiving ADT and whether EBRT was performed in conjunction with BT were 
provided in most studies. 
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Data Source  
(study interval) 
Median follow-up  
duration (RP/RT), 
months 
RP (n) RT (n) 
Median (IQR) age  
(RP/RT), years 










355 63.8/66.1 na ADT: 
RT: "majority" 
RP: na EBRT±ADT 
 v RP /62 2638 /69.4  
Jayadevappa 2019 
EBRT+BT±ADT 





4141 71.7/73.1 na not reported 
EBRT+ADT 




Gunnarsson 2019 EBRT±BT±ADT 
 v RP+RT+ADT 
Kalmar County Hospital, 
Sweden (RP);  
The National Prostate 
Cancer Register (RT) (1995, 
2010) 









 v RP+ADT 
Hospital General 
Universitario  
Gregorio Maran ̃ón, Madrid, 
Spain (1996, 2008) 






 v RP 
Chicago Prostate Cancer 
Centre (RT); Martini-Klinik 






BT (I125 Pd103 






v RP+ADT 46.4/ 88 66.6/ RP: 100% 
aRT: 0% 
v RP+aRT 58.6/ 49 66/ RP: 0% 
aRT: 100% 
v 
RP+ADT+aRT 57.4/ 50 66.4/ 
RP: 100% 
aRT: 100% 
Robinson 2018 EBRT±BT±ADT 
 v RP 
Swedish National Prostate 
Cancer Registry (1998, 2012) 75.6/70.8 3761 6462 63.1/67 na not reported 
Ciezki 2017 
EBRT 
 v RP 





(52%) at 78 (2 
Gy fraction)  
& (48%) at 70 











 v RP 
Multi-institutional  
(12 centres) (2000, 2013) 
50.4/61.2 
639 












Greenberg 2015 EBRT+ADT 
 v RP 
Anglia Cancer Network,  




Lee 2014 EBRT±ADT 
 v RP 
Severance Hospital, Seoul, 
Korea (1990, 2009) 74/85.5 251 125 67.5/68.6 
EBRT (range)  
74-79 not reported 
Yamamoto 2014 EBRT±ADT 
 v RP 
Cancer Institute Hospital in 




Westover 2012 EBRT+BT+ADT 
 v RP 
Duke University (RP) (1988, 
2008); Chicago Prostate 
Cancer Centre /21st Century 
Oncology Establishment (RT)  
(1991, 2005) 










 v RP Barnes-Jewish Hospital  
and Cleveland Clinic  
(1995, 2005) 









RP: na EBRT+BT 
 v RP 
(59 to 72)/(51 to 
70) 33 /68.4  
Boorjian 2011 
EBRT 
 v RP Mayo Clinic Prostatectomy  
Registry (RP) and the Fox  














Abbreviations: RP = radical prostatectomy; RT = radiation therapy; Gy = Gray; EBRT = external beam radiation 
therapy; BT = brachytherapy; SEER = Surveillance, Epidemiology, and End Results Program; ADT = androgen 
deprivation therapy; I125 = Iodine-125; Pd103 = Palladium-103; Cs131 = Cesium-131 
 
 
6.3.2 Risk of bias assessment 
 
 The overall risk of bias was high for all studies (Table 6.2), as none examined all 
potential confounders and applied adjustments as appropriate. Most studies had a low risk of 
bias for the ‘selection’ section other than those comparing treatment groups from tertiary 
centers. The ‘comparability’ section varied due to variation in covariate control. All studies 
controlled for age, most studies provided adequate control for tumor characteristics (i.e., PSA, 
clinical stage, and Gleason scores) (13/14), while fewer studies controlled for comorbidities 
(7/14), demographic characteristics (4/14) and study center (7/14). Finally, most studies did not 
have a sufficient median follow-up, leading to a score of 2/3 for the ‘outcome’ section for 12/14 
studies. There was no indication of publication bias. The Egger test for publication bias was not 
statistically significant (p = 0.22 for CSM and 0.92 for ACM; Figure 6.2). 
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Figure 6.2 Funnel plots of meta-analysis for (a) prostate cancer-specific mortality, and 
(b) all-cause mortality using random-effects models. Mixed-effects models with 
moderators to reduce heterogeneity in effect estimates and improve symmetry in funnel 
plots for assessment of publication bias are shown in (c) for CSM (adjusted for receipt 
of BT) and (d) for all-cause mortality (adjusted for receipt of BT and age). 




Table 6.2 Modified Newcastle-Ottawa Scale for risk of bias assessment of studies included in the meta-
analysis 
Study Information Selection 
Author (Year) 
Representativeness  
of the exposed  
cohort (RT) 
Representativeness 




Demonstration that  
outcome of interest  
was not present at start 
Total 
Yin (2019) 1 1 1 1 4 
Jayadevappa (2019) 1 1 1 1 4 
Gunnarsson (2019) 1 0.5 1 1 3.5 
Cano-Velasco (2019) 0.5 0.5 1 1 3 
Tilki (2018) 0.5 0.5 1 1 3 
Robinson (2018) 1 1 1 1 4 
Ciezki (2017) 0.5 0.5 1 1 3 
Kishan (2017) 1 1 1 1 2 
Greenberg (2015) 1 1 1 1 4 
Lee (2014) 1 1 1 1 4 
Yamamoto (2014) 0.5 0.5 1 1 3 
Westover (2012) 0.5 0.5 1 1 3 
Kibel (2012) 1 1 1 1 4 
Boorjian (2011) 0.5 0.5 1 1 4 
 Comparability 
Author (Year) cT GS PSA Age Comorbidity 
Demographic 
characteristic 





Yin (2019) 1 1 1 1 0 1 1 1 3.5 
Jayadevappa (2019) 0 0 0 1 1 1 1 1 2.5 
Gunnarsson (2019) 0.5 0.5 0.5 1 0 1 0 0 1.75 
Cano-Velasco (2019) 1 1 1 1 0 0 0 1 2.5 
Tilki (2018) 1 1 1 1 1 1 0 0 3 
Robinson (2018) 1 1 1 1 1 1 1 0 3.5 
Ciezki (2017) 1 1 1 1 0 0 0 1 2.5 
Kishan (2017) 1 1 1 1 0 0 0 1 2.5 
Greenberg (2015) 1 1 1 1 0 0 0 0 2 
Lee (2014) 1 1 1 1 1 1 0 1 3.5 
Yamamoto (2014) 1 1 1 1 1 0 0 1 3 
Westover (2012) 1 1 1 1 1 1 0 0 3 
Kibel (2012) 1 1 1 1 1 0 1 0 3 









Total Risk of Bias 
Yin (2019) 1 1 0 2 High 
Jayadevappa (2019) 1 1 0 2 High 
Gunnarsson (2019) 1 1 0 2 High 
Cano-Velasco (2019) 0 1 1 2 High 
Tilki (2018) 1 1 0 2 High 
Robinson (2018) 1 1 0 2 High 
Ciezki (2017) 1 1 0 2 High 
Kishan (2017) 1 1 0 2 High 
Greenberg (2015) 1 1 0 2 High 
Lee (2014) 1 0 0 1 High 
Yamamoto (2014) 1 1 0 2 High 
Westover (2012) 1 1 0 2 High 
Kibel (2012) 1 1 0 2 High 
Boorjian (2011) 1 1 1 3 High 
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Table 6.3. Subgroup analyses assessing risk of prostate cancer-specific mortality and all-cause 
mortality following radiotherapy and surgery for prostate cancer 
 Prostate cancer-specific mortality Overall mortality 
 
Adjusted HR (95% CI; p-value) I2 






EBRT±ADT 1.35 (1.10, 1.67; p=0.0048) 59% 1.54 (1.14, 2.09; p=0.0054) 91% 
EBRT+BT±ADT 0.68 (0.48, 0.95; p=0.024) 47% 0.89 (0.55, 1.44; p=0.64) 86% 
Treatment Era   
Before 2002 1.03 (0.75, 1.42; p=0.84) 69% 1.45 (0.92, 2.30; p=0.11) 97% 
After 2002 1.00 (0.76, 1.30; p=0.98) 71% 1.00 (0.71, 1.42; p=0.99) 73% 
Age   
≤67.4 years 1.04 (0.84, 1.29; p=0.72) 59% 1.58 (1.36, 1.85; p<0.0001) 39% 
>67.4 years 0.97 (0.63, 1.47; p=0.87) 77% 0.94 (0.62, 1.43; p=0.78) 95% 
Median follow-up     
≤67 months 1.04 (0.82, 1.32; p=0.73) 63% 1.06 (0.62, 1.81; p=0.83) 83% 
>67 months 0.98 (0.67, 1.41; p=0.90) 74% 1.28 (0.83, 1.98; p=0.27) 97% 
Geographic region     
United States 1.10 (0.87, 1.38; p=0.42) 71% 1.35 (0.90, 2.01; p=0.14) 97% 
Other 0.81 (0.49, 1.32; p=0.40) 62% 1.01 (0.61, 1.66; p=0.98) 77% 
Abbreviations: HR = hazard ratio; CI = confidence interval; EBRT = external beam radiation therapy; BT = 
brachytherapy; ADT = androgen deprivation therapy  
 
6.3.4 Prostate cancer-specific mortality 
 
Ten studies with 88,026 patients were included in the primary meta-analysis for CSM. 
The resulting adjusted hazard ratio [95% confidence interval] was 1.02 [0.84, 1.25] with 
substantial heterogeneity (I2=69%) as shown in Figure 6.3a. Moderator analysis revealed a 
statistically significant effect by RT approach (p<0.0001). Specifically, CSM was increased among 
EBRT±ADT compared to RP (1.35 [1.10, 1.68]; p=0.0048), but decreased among EBRT+BT±ADT 
compared to RP (0.68 [0.48, 0.95]; p=0.024) (Table 6.3; Figure E6.1a). Including this variable in 
the moderator analysis was also associated with decreased, though still substantial, 
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heterogeneity (I2=59% and 47%, respectively). The remaining moderator analyses did not differ 
notably from the primary analysis. 
 
6.3.5 All-cause mortality 
 
Seven studies with 74,210 patients were included in the secondary meta-analysis for 
ACM. The resulting adjusted HR [95%CI] was 1.21 [0.89, 1.65] with substantial heterogeneity 
(I2=95%) as shown in Figure 6.3b. Moderator analysis revealed a statistically significant effect by 
RT approach (p=0.03). Specifically, ACM was increased among EBRT±ADT compared to RP (1.54 
(1.14, 2.09; p=0.0054)), but no statistically significant difference among those treated with 
EBRT+BT±ADT relative to RP (0.89 (0.55, 1.44; p=0.64)) (Table 6.3; Figure E6.1b). Both 
moderator analyses were associated with substantial heterogeneity (I2=91% and 86%, 
respectively). Moderator analysis by median age also revealed a significant effect (p=0.0001). A 
statistically significantly higher rate of ACM among RT relative to RP was observed among 
studies with younger patient groups (1.58 [1.36, 1.85]; p<0.0001; I2=39%) compared to those 
with older patient groups (0.94 [0.62, 1.43]; p=0.78; I2=95%) (Table 6.3; Fig E6.2b). Effect 
estimates also varied from the main analysis among moderator analyses of studies assessing 
men diagnosed and/or treated before 2002 (1.45 [0.92, 2.30]), but not after 2002 (1.00 [0.71, 
1.42]) median follow-up of >67 months (1.28 [0.83, 1.98]), but not ≤67 months (1.06 (0.62, 
1.81), and studies performed in the United States (1.35 [0.90, 2.01]) versus other geographic 
locations (1.01 [0.61, 1.66]).  
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Figure 6.3 Forest plot assessing the risk of (a) prostate cancer-specific mortality and (b) all-
cause mortality following radiotherapy and surgery for prostate cancer 




 Our aggregate effect estimates for adjusted CSM showed no statistically significant 
differences between RP and RT for high-risk non-metastatic PCa patients. Moderator analysis 
revealed a significant increased incidence of CSM among men treated with EBRT±ADT relative 
to the RP group and a decreased incidence of CSM among men treated with EBRT+BT±ADT 
relative to the RP group. This is consistent with results from the ASCENDE-RT trial wherein an 
increased incidence of biochemical failure was found among men diagnosed with intermediate- 
and high-risk non-metastatic PCa and treated with dose-escalation RT protocols using EBRT 
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alone compared with those using combination EBRT+BT (HR [95%CI]: 2.04 [1.25, 3.33]).(167) 
Remaining moderator analyses did not differ from the primary analysis. 
Multiple reports indicate that, since the early 2000’s, the use of BT boost in high-risk 
patients has declined in use in the United States,(201) and other geographic regions.(202) 
Interestingly, however, the use of prostate BT boost has increased since the early 2000’s in 
certain European centers and in Canada.(203,204) This discrepancy may be attributable to 
differences in resident exposure in providing sufficient training opportunities given the steep 
learning curve associated with administering BT,(205–207) and unfavorable reimbursement 
relative to EBRT in the United States relative to publicly funded healthcare systems.(203,208) 
Given the CSM benefit associated with BT boost among high-risk patients reported in RCTs and 
estimated here, we encourage investment in overcoming the aforementioned obstacles 
through increasing resident exposure, and improving reimbursement models to encourage use 
BT boost.  
The HR comparing relative incidence of CSM between EBRT±ADT and RP groups was 
smaller compared to that in a previous meta-analysis performed in 2016 (1.35 [1.10, 1.68] 
versus 1.83 [1.51–2.22]).(118) These differences might be explained by more recent changes in 
treatment approaches including the increasing use of dose-escalation protocols and adjuvant 
ADT paired with RT,(201,202) which have both demonstrated improvements in oncological 
outcomes, though only the addition neoadjuvant ADT to RT has demonstrated improvements in 
CSM.(91,186,202)  
 The analysis of relative ACM between RT and RP also revealed no statistically significant 
difference between the treatment groups. However, moderator analysis revealed a statistically 
 114 
significantly increased incidence of ACM among the EBRT±ADT relative to the RP group, while 
there was an insignificant decrease in ACM between the EBRT+BT±ADT and RP groups. In 
addition to the CSM benefit afforded through RP and EBRT+BT±ADT relative to EBRT±ADT, 
differences in cardiopulmonary health requirements before undergoing general anesthetic that 
is required for RP and BT, and lack of control for comorbidities in many of the included studies 
might contribute to the observed differences. Studies conducted among younger age groups 
demonstrated increased incidence of ACM in the RT relative to the RP group. Finally, a 
tendency toward increased incidence of ACM in the RT relative to the RP group was also noted 
when restricting analyses among studies conducted in earlier treatment eras, longer follow-up 
periods and among studies conducted only in the United States. However, this is likely 
explained by the greater proportion of comparisons with RP involving EBRT±ADT instead of 
EBRT+BT±ADT among studies conducted in earlier treatments eras, which were associated with 
longer follow-up periods and were mostly performed in the United States versus other 
geographic locations. 
Overall, the risk of bias was deemed high for all studies due to the partial control of 
confounding variables. This stands in contrast with a previous meta-analysis performed by 
Wallis et al who found a low to moderate risk of bias for all studies included in their meta-
analysis comparing the rate of ACM and CSM between patients who underwent RT and RP. 
Interestingly, four studies used in both analyses indicated perfect comparability between RT 
and RP groups by Wallis et al., yet some of these studies did not control for study 
center,(92,209,210) year of diagnosis,(100,209,210) or demographic characteristics.(92) Since 
patients undergoing RT are more likely to be older, have poorer prognostic characteristics, and 
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sociodemographic characteristics that are associated with poorer CSM and ACM,(211–213) we 
anticipate the influence of these unaccounted-for biases to overestimate CSM and ACM in the 
RT group relative to the RP group. However, the discrepancy in such baseline characteristics 
appears more prominent among those undergoing EBRT±ADT rather than EBRT+BT±ADT 
wherein patients are more similar to those undergoing RP.(211,212) As such, collecting 
information on these variables and properly controlling for them is crucial when estimating 
relative treatment effects between groups to more accurately inform treatment decisions. 
Our study has certain limitations. There was a high level of heterogeneity in effect 
estimates. This was substantially reduced through moderator analyses comparing RP with 
EBRT±ADT and EBRT+BT±ADT, and among comparisons involving younger populations, though 
heterogeneity still remained high and was unaccounted for through additional moderator 
analyses. Unfortunately, information surrounding treatment details such as RT dose, type of 
EBRT (i.e., 3D conformal, IMRT, etc.), use of adjunct therapies and surgeon experience, which 
might account for a large proportion of this heterogeneity, was missing in many of the studies.  
Given the high risk of bias in all studies, the aggregated effect estimates provided in this 
study are limited in informing clinical decisions. In light of this and considering the relatively 
small difference in CSM between treatment approaches, other factors such as patient 
preferences, patient health (i.e., comorbidities), and treatment factors (e.g., operative risk and 
prostate volume for BT) should be considered when forming treatment decisions. This should 
occur through a shared decision-making process, involving the patient and providing urologist 





  We identified no statistically significant difference in the rate of CSM between patients 
diagnosed with high-risk non-metastatic PCa and treated with RP relative to RT. However, there 
was significant subgroup effect with the use of EBRT+BT±ADT, highlighting the necessity of 
differentiating RT with or without BT in future comparative effectiveness studies. The high risk 
of bias in all studies reviewed emphasizes the need for better control of all potentially 
confounding variables to provide higher quality non-randomized evidence. This is exceedingly 
important when RCTs are unlikely to be feasible in this patient population.(110,111) 
 
6.6 Transition to Chapter Seven 
 
 In this chapter, we found no difference in the rate of CSM between men diagnosed with 
high-risk non-metastatic PCa who were initially treated with RT or RP. Although differences in 
outcomes seemed to depend on RT type and age. Moreover, the risk of bias for all included 
studies was high. This was mainly due to inadequate control for all observable confounding 
variables, which might have been due to limitations in data collection and/or 
inadequate/inappropriate management of confounding. The results from this systematic review 
and meta-analysis provide context for the following chapter, which compared MPFS, a 
validated surrogate for CSM, between men diagnosed with unfavorable-risk non-metastatic PCa 
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Identifying the optimal management of unfavorable-risk non-metastatic prostate cancer (PCa) 
is an important public health concern given the large burden of this disease. We compared the 
rate of metastatic progression-free survival among men diagnosed with unfavorable-risk non-
metastatic PCa and treated with radiation therapy (RT) or radical prostatectomy (RP).  
Methods 
 
We reviewed medical records obtained from two academic centers in Toronto and London, 
Ontario, Canada of men diagnosed with unfavorable-risk non-metastatic PCa and treated with 
primary RT or RP. Patients were matched on prognostic covariates using two matching 
techniques. Multivariable Cox proportional hazards models were used to estimate the hazard 
ratios and confidence intervals for metastatic progression-free survival between groups. 
Results 
 
A total of 164 and 169 men were included in the RT and RP treatment groups, respectively.  
After a median follow-up of 83.9 and 96.9 months of men in the RT and RP groups, respectively, 
no difference in the rate of metastatic progression-free survival was found between groups 
(unadjusted HR [95%CI]: 1.29 [0.74, 2.26]; p=0.37 and adjusted: 1.16 [0.63, 2.13]; p=0.64). 
Effect estimates did not change notably after matching. 
Conclusion 
 
The rate of metastatic progression-free survival did not differ between men diagnosed with 
unfavorable-risk non-metastatic PCa who were treated with either RT or RP.  
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7.1 Background and Rationale 
 
Prostate cancer (PCa) was the second leading cancer diagnosis and fifth leading cause of 
cancer death globally in 2018.(3) Unfavorable-risk non-metastatic disease, including high-
intermediate, high and extremely high-risk disease,(19) accounts for approximately one third of 
all PCa diagnoses, but a disproportionate amount of morbidity and mortality.(180,202,214) 
Optimizing the efficacy and safety of treatments for this disease is thus a major public health 
concern. Common definitive management options include surgical resection of the prostate 
(radical prostatectomy [RP]) and irradiation of the prostate through radiation therapy (RT).(21) 
Compared to watchful waiting, definitive management with RT or RP among men diagnosed 
with localized PCa has been shown in RCTs to decrease the rate of metastatic progression, PCa-
specific mortality and overall mortality.(87,215) 
The selective use of adjuvant and salvage therapies alongside definitive management 
has also been shown to further improve outcomes. For instance, the use of adjuvant RT in the 
context of adverse pathological findings post-RP has been found to decrease rates of 
biochemical recurrence and local relapse.(216–218) The addition of androgen deprivation 
therapy (ADT) to RT post-RP has been shown to reduce rates of metastatic progression and 
PCa-specific mortality among those with adverse pathological features relative to RT alone. For 
patients with unfavorable-risk non-metastatic PCa who undergo RT, decreased risk of 
metastatic progression and PCa-specific death has been observed with the use of adjuvant 
ADT.(105,219) Results from the ASCENDE-RT trial have also shown improvements in 
biochemical control from combination external beam RT (EBRT) with BT compared to EBRT 
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alone.(167) Finally, RT dose-escalation protocols have demonstrated improvements in 
biochemical control such that traditional regimens of <70 Gy are no longer standard.(21) 
Despite the progress made in the selection and sequencing of adjuvant and salvage 
therapies and refinements in RT approaches, optimal local control has not been adequately 
evaluated through a RCT for this patient population. In turn, clinicians and patients rely on 
evidence generated from observational data to guide treatment decisions, which have 
limitations due to confounding and comparisons involving outdated treatment regimens. For 
example, candidates for RP compared to RT generally have less aggressive tumor 
characteristics, are younger and with fewer comorbidities.(114) Vast disparities in these 
baseline characteristics make the assumptions of positivity required for valid estimation of 
treatment effects through regression modeling questionable.(183) As such, identifying patients 
with similar baseline characteristics who are treated with RP and RT and who have undergone 
more contemporary forms of treatment is necessary to improve the internal and external 
validity of evidence on this topic. 
In this study, we compared the rate of metastatic-progression between men diagnosed 
with unfavorable-risk non-metastatic PCa and treated with RT and RP as definitive local 
therapies. Issues of non-positivity are mitigated through the use of data obtained from a 
multidisciplinary clinic wherein RT patients were also eligible for RP. Furthermore, we take 
advantage of data preprocessing techniques that have been developed to improve the degree 
of comparability between treatment groups obtained from observational data.(138,139) 






7.2.1 Data source 
 
Ethics approval was provided from both institutional review boards at Sunnybrook 
Health Sciences Centre and London Health Science Centre (LHSC). We identified the records of 
men diagnosed between 2007-2012 with high-intermediate to extremely high-risk non-
metastatic PCa in the multi-disciplinary diagnostic assessment program in the Gale and Graham 
Wright Prostate Centre (GGWPC) at North York General Hospital in Toronto, Ontario, Canada. 
Patients in the RT group included those who had undergone EBRT with or without 
brachytherapy boost (BT) (low-or high dose rate) and with or without ADT. Patients in the RP 
group included those who had undergone RP as their primary treatment modality. Due to 
limited RP observations from the GGWPC, we also included men diagnosed between 2007-2012 
with high-intermediate to extremely high-risk non-metastatic PCa who were treated with 
primary RP at LHSC in London, Ontario, Canada.  
 
7.2.2 Data Collection 
 
We reviewed electronic medical records from identified patients. Information regarding 
patient age at diagnosis, biopsy date, prognostic factors at diagnosis (pre-biopsy PSA level, TNM 
stage, Gleason Score (GS), and percentage of biopsy cores containing tumor), initial treatment 
decision, treatment date, and treatment details were obtained. Patients were eligible for the 
study if they met the following criteria: 
 123 
1. Diagnosed with high-intermediate, high or extremely high-risk PCa according to the 
Prostate Cancer Risk Stratification (ProCaRS) database.(19)  
2. No evidence of regional or metastatic disease at the time of diagnosis and staging 
3. Consulting radiation oncologist offered the RT 
4. Consulting urologist offered patient RP 
5. Diagnosed between July 2007 and December 2012 
6. Had at least one year of follow-up 
 
ProCaRS high intermediate-risk disease (HIR) is defined as having a GS=7 and one or 
both of PSA 10-20 ng/mL and/or bilateral clinical disease. High-risk disease (HR) is defined as 
having a PSA > 20 ng/mL, cT stage = 3-4 or GS = 8-10, while extremely high-risk disease (EHR) is 
defined as having a PSA > 30 ng/mL or high-volume disease, defined as > 87.5% biopsy core 
involvement. Information on patient comorbidities, socioeconomic and demographic 





 We analyzed the rate of metastatic progression-free survival between treatment 
groups. Metastatic progression was confirmed through imaging reports. Progression-free 
survival time was defined as the interval between the date of PCa treatment initiation (i.e., RT 
or RP) and the date of metastatic progression or last documented encounter with their 
providing oncologist. Patients who were event-free at the end of the study period were 
 124 
censored at that point and contributed the time interval from their date of treatment to the 
end of the study in the survival analysis. 
 
7.2.4 Covariate selection 
 
We explored the potential for confounding through examining differences between 
treatment groups in distributions of baseline covariates that have demonstrated a prognostic 
role in relation to the rate of treatment failure in previous literature.(19) Covariates included 
tumor characteristics (i.e. pre-biopsy PSA level, clinical T (cT) stage, and GS). Age was not 
included as a covariate since it has not demonstrated a predictable association with the 
outcome examined in previous research,(176,177) nor did it demonstrate an association in 
either of the comparisons performed here (adjusted for treatment received: HR [95%CI]: 0.98 
[0.93, 1.03]; p-value=0.50 and HR [95%CI]: 1.00 [0.98, 1.02]; p-value=0.99 for datasets used in 
comparison one and two, respectively). Further, age was strongly associated with treatment 
choice, which would bias effect estimates if adjusted for.(168) An insufficient number of 
patients had specific information related to the percentage of tumor containing biopsy cores. 
Thus, this variable is only reported in the descriptive statistics and not used for adjustment. 
 
7.2.5 Propensity score matching 
 
The propensity score model was a logistic model with prognostic characteristics as 
independent variables and type of treatment received as a binary dependent variable.(168) We 
explored the possibility of interactions and non-linearity for baseline covariates when fitting the 
propensity score model.(152,178) Locally weighted scatterplot smoothers were used to assess 
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for departures from linearity in the relationship between baseline PSA and the logit of the 
probability of receiving RP. Improvements in the model fit were assessed using the likelihood 
ratio test and pseudo-R2. DFBETA statistics did not reveal any outliers. Model one involved 
baseline PSA as a linear term and cT stage (1a, 1b, 1c, 2a, 2b, 2c, 3a, 3b, 3c, 4a, and 4b) and GS 
(6, 7, 8, 9, 10) as categorical variables. A restricted cubic spline with four knots was found to 
improve model fit for baseline PSA, and thus was included in model two. The MatchIt package 
in R was used to match participants with a ratio of 1:1 between treatment groups.(146) 
Although chapters four and five used many-to-one and one-to-many matching ratios, the 
number of participants in those comparisons varied substantially between treatment groups. 
Here, the number of participants in each treatment group is approximately the same so a 1:1 
matching ratio was used. We explored a range of caliper widths between 1.0 and 0.01 standard 
deviations of the logit of the propensity score. Nearest-neighbour matching was used without 
replacement.(179)  
 
7.2.6 Coarsened exact matching 
 
Patients were matched on progressively coarsened covariates (i.e., GS, cT stage, and 
baseline PSA). GS was first dichotomized into ≤7 or 8-10 and then using each category (6, 7, 8, 
9, and 10). Clinical T stage was first dichotomized into ≤2 and 3-4 and then using each category 
(1a, 1b, 1c, 2a, 2b, 2c, 3a, 3b, 3c, 4a and 4b). Due to missing information, categorizing GS in 
more detail (i.e., GS=7 as 3+4 vs 4+3) was not feasible without substantial data loss. Progressive 
coarsening for PSA involved cut points from 0 ng/ml to 300 ng/ml first at 20 and 100 ng/ml, 
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with additional cut points at 30 and 50 ng/ml and further at 6 and 10 ng/ml. Coarsening ranges 
are presented in S Table 1.  
 
7.2.7 Balance diagnostics 
 
 Many balance diagnostics exist and have been rigorously assessed using various 
empirical and simulation datasets that represent a broad range of data characteristics. We 
chose four balance measures that considered different data characteristics in order to monitor 
improvements in balance when further restricting matching strategies (i.e., using finer ranges 
for covariates in coarsened exact matching and smaller caliper widths in propensity score 
matching). This enabled systematic identification of matching strategies that optimized balance 
in the multivariable distribution of baseline covariates as a function of data retention. This 
process is shown in Figures E1&2 for both matching strategies. 
 
7.2.8 Descriptive statistics and multivariable regression analysis 
 
 All statistical analyses were performed using RStudio version 3.6.0.(169) Descriptive 
statistics were calculated for each treatment group before and after matching. The mean and 
standard deviation are presented for continuous variables and proportions for categorical 
variables. MPFS was plotted for each group using Kaplan-Meier curves and the log-rank test 
was used to calculate if MPFS significantly differed between groups. Cox proportional-hazards 
regression analyses were performed for estimating the effect of treatment group on the hazard 
of metastatic progression using the Survival package.(181) The proportional-hazards 
assumption was confirmed using log-minus-log survival plots and scaled Schoenfeld residuals. 
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Improvements in model fit were examined through comparing the model log likelihoods after 
incorporating interaction terms and higher order terms and transformations for continuous 
covariates. Examination of a plot of DBETA statistics did not identify any influential 
observations. Hazard ratios and 95% confidence intervals were calculated from unmatched data 
both without and with adjustment for baseline PSA, cT stage, and GS as well as interactions 
between baseline PSA and GS and baseline PSA and cT stage. For matched data, we employed 
Cox models clustered by the matched sets, using robust variance estimators to generate 




 Descriptive characteristics are displayed in Table 1. At diagnosis, men treated with RT 
relative to RP were older, had higher PSA levels, a greater percentage of tumor containing 
biopsy cores, less advanced tumor staging, and comparable GS. A greater proportion of men 
treated with RT presented with high-intermediate risk, and a smaller proportion of high-risk 
disease than those treated with RP, while similar proportions of each treatment group were 
considered extremely high-risk disease.  
Sixty-seven (40.9%) men treated with RT received neoadjuvant ADT compared to only 
40 (23.7%) men treated with RP. Twenty-eight (17.1%) of men treated with RT received 
adjuvant ADT, while over 43% of the RP group did. Local and systemic salvage therapy was 
initiated among 30.8% and 28.4%, respectively, among men treated with RP, while only one 
man (0.6%) treated with RT received systemic salvage therapy aside from adjuvant ADT. The 
most common form of RT was EBRT without BT boost for which 84.6% of men received. The 
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median dose for men receiving EBRT without BT boost was 78 Gy. Of the 19 (11.2%) of men 
who received BT boost, the vast majority received HDR, while only one (0.6%) man received 
LDR. Finally, two men (1.2%) treated with RT received SBRT boost. The median dose for this 
group was 113.57 Gy. 
 Descriptive characteristics after matching are displayed in Table 2. After propensity 
score matching, 117 subjects were retained in each group, while coarsened exact matching led 
to retention of 138 and 141 patients from the RT and RP groups, respectively. Both matching 
strategies led to balance in the multivariable covariate structure according to conventional 
thresholds for balance (i.e., SMD<0.1 and variance ratio between 0.92 to 1.08).(152) Mean 
percent of tumor containing biopsy cores remained imbalanced. 
 Kaplan-Meier curves showing the probability of metastatic progression-free survival 
over time stratified by treatment group are shown in Figure 2. Overall, both treatment groups 
demonstrated similar rates of metastatic progression-free survival over time. Unadjusted and 
adjusted hazards ratios and 95% confidence intervals are presented in Table 3. The unadjusted 
HR [95%CI] estimated before matching was 1.29 [0.74, 2.26], which attenuated to 1.16 [0.63, 
2.13] upon adjustment. The HR [95%CI] was 1.06 [0.50, 2.26] after propensity score matching 
and 1.55 [0.60, 3.98] after coarsened exact matching. Given the small number of events, 
variation in the effect estimates might be attributable to random error. Moreover, changes in 
the effect estimates are expected with sample changes due to matching. 
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N=164 N=169   N=75 N=94   
Follow-up time 
(months) 












Metastatic Events  
n (%) 
20 (12.2) 33 (19.5) 0.20  11 (14.7) 22 (23.4) 0.22 
 
Age (years) at 
Diagnosis, Mean (SD) 
72.5 (7.5) 62.6 (6.4) 
1.42 0.74 
62.1 (6.7) 63.6 (5.9) 
0.15 0.83 
Missing n (%) 3 (1.8) 0 (0) 0 (0) 0 (0) 
Baseline PSA (ng/ml) 
Mean (SD) 
19.7 (21.9) 16.4 (15.3) 
0.18 0.49 
14.4 (10.9) 17.9 (18.0) 
0.24 2.70 
Missing n (%) 1 (0.6) 0 (0) 0 (0) 0 (0) 
Clinical T Stage         
1 75 (48.4) 65 (40.1) 0.17  43 (62.3) 22 (23.7) 0.85  
2 67 (43.2) 57 (35.2) 0.17  20 (29.0) 37 (39.8) 0.23  
3 13 (8.4) 37 (22.8) 0.41  6 (8.7) 31 (33.3) 0.63  
4 0 (0) 3 (1.9) 0.19  0 (0) 3 (3.2) 0.26  
Missing n (%) 9 (5.5) 7 (4.1)   6 (8.0) 1 (1.1)   
Gleason Score         
≤6 4 (2.4) 5 (3.0) 0.03  2 (2.9) 3 (3.2) 0.03  
7 108 (65.9) 103 (61.0) 0.10  46 (66.7) 55 (58.5) 0.13  
8 20 (12.2) 31 (18.3) 0.17  7 (10.1) 22 (23.4) 0.30  
9 32 (19.5) 28 (16.6) 0.08  14 (20.3) 13 (13.8) 0.17  
10 0 (0) 2 (1.2) 0.15  0 (0) 1 (1.1) 0.02  
Missing n (%) 0 (0) 0 (0)   0 (0) 0 (0)   
(%) Core Positivity 
Mean (SD)  
56.4 (27.8) 51.0 (25) 0.20 0.81 50.5 (24.2) 51.7 (25.6) 0.06 1.14 
≥50% 97 (59.2) 93 (59.2) 0.00  39 (56.5) 48 (63.2) 0.18  
Missing n (%) 0 (0) 12 (7.1)   0 (0) 12 (12.8)   
ProCaRS Risk-Groups         
High-Intermediate 72 (47.4) 58 (40.6) 0.14  29 (45.7) 29 (38.7) 0.08  
High 48 (31.6) 59 (41.3) 0.20  27 (39.7) 32 (42.7) 0.06  
Extremely High 32 (21.1) 26 (18.2) 0.07  12 (17.7) 14 (18.7) 0.03  
Missing n (%) 12 (7.3) 26 (18.4)   7 (10.4) 19 (20.2)   
Treatment Characteristics 
Radiotherapy Patients 
EQD2 for EBRT 
Median (min, max) 
78  
(70, 108.5) 
       
EQD2 for EBRT+BT 
Median (min, max) 
113.57 
(113.1, 116.7) 
       
ADT n (%) 95 (57.9)        
Initial ADT n (%) 67 (40.9)        
Duration ADT 
Median (min, max) 
22.1  
(2.5, 43.3) 
       
Brachytherapy boost type 
Low-dose rate 1 (0.6)        






 40 (23.7)   2 (2.7) 38 (40.4)   
Adjuvant 
radiotherapy 
 57 (33.7)   
9 (12) 48 (51.1) 
  
Adjuvant systemic  32 (18.9)   8 (10.7) 24 (25.5)   
All patients 
Local salvage 0 (0) 52 (30.8)   36 (48.0) 16 (17.0)   
Systemic salvage 1 (0.6) 48 (28.4)   20 (26.7) 28 (29.8)   
Abbreviations: |SMD| = absolute standardized mean difference; LHSC = London Health Sciences Centre; RP = Radical Prostatectomy; 




Figure 7.2 Kaplan-Meier curves showing the probability of metastatic progression-free 




Table 7.2 Descriptive patient characteristics in matched samples 














N=117 N=117   N=138 N=141   
Age at Diagnosis 
Mean (SD) 
72.3 (7.4) 62.1 (6.5) 
1.46 1.28 
72.4 (7.3) 62.6 (6.3) 
1.45 1.39 










Missing n (%) 0 (0) 0 (0) 0 (0) 0 (0) 
Clinical T Stage         
1 58 (49.6) 63 (53.9) 0.09  71 (51.5) 73 (51.5) 0  
2 47 (40.2) 44 (37.6) 0.05  58 (42.0) 59 (42.0) 0  
3 12 (10.3) 10 (8.6) 0.06  9 (6.5) 9 (6.5) 0  
4 0 (0) 0 (0) 0  0 (0) 0 (0) 0  
Missing n (%) 0 (0) 0 (0)       
Gleason Score         
≤6 3 (2.6) 3 (2.6) 0  2 (1.4) 2 (1.4) 0  
7 80 (68.4) 80 (68.4) 0  98 (71.0) 100 (71.0) 0  
8 17 (14.5) 15 (12.8) 0.05  15 (10.9) 15 (10.9) 0  
9 17 (14.5) 19 (16.2) 0.05  23 (16.7) 24 (16.7) 0  
10 0 (0) 0 (0) 0  0 (0) 0 (0) 0  
Missing n (%) 0 (0) 0 (0)       
(%) Core Positivity 
Mean (SD)  
57.7 (27.8) 49.2 (24.2) 0.33 1.33 
56.0 
(27.0) 
49.0 (22.0) 0.26 1.51 
≥50% 75 (64.1) 63 (54.8) 0.19  83 (60.1) 80 (58.6) 0.03  
Missing n (%) 0 (0) 2 (1.7)   0 (0) 9 (6.4)   
ProCaRS Risk-
Groups 
        
High-Intermediate 57 (50.9) 54 (48.2) 0.05  72 (54.5) 76 (57.9) 0.07  
High 35 (31.3) 40 (35.7) 0.09  41 (31.1) 41 (31.2) 0.00  
Extremely High 20 (17.9) 18 (16.1) 0.05  19 (14.4) 14 (10.9) <0.10  
Missing n (%) 5 (4.3) 5 (4.3)   6 (4.3) 9 (6.4)   
Abbreviations: |SMD| = absolute standardized mean difference; LHSC = London Health Sciences Centre; RP = Radical 
Prostatectomy; ADT = androgen deprivation therapy; RT = radiation therapy 
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Table 7.3 Hazards ratios and confidence intervals for metastatic progression in RP relative to RT 
 Unadjusted *Adjusted 
 Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value 
Unmatched 1.29 0.74, 2.26 0.37 1.16 0.63, 2.13 0.64 
PSM 1.01 0.50, 2.05 0.64 1.06 0.50, 2.26 0.87 
CEM 1.32 0.62, 2.82 0.47 1.55 0.60, 3.98 0.37 
Abbreviations: RP = radical prostatectomy; RT = radiation therapy; PSM = propensity score matched; CEM = coarsened exact 
matched; CI = confidence interval 
*Adjusted model includes baseline PSA, clinical T stage, and Gleason score as continuous linear variables with interactions 




 We compared the rate of metastatic progression between men diagnosed with 
unfavorable-risk non-metastatic PCa who were treated with RT or RP. No significant difference 
was observed in the rate of metastatic progression between treatment groups. Previous 
reports have demonstrated reduced rates of metastatic progression among men diagnosed 
with unfavorable-risk non-metastatic PCa who were initially treated with RT relative to 
RP.(220–222) This includes a very similar study of men diagnosed with high- and very high-risk 
PCa in a multidisciplinary clinic and treated with RT or RP wherein rates of distant metastasis 
were elevated among those treated with RP relative to those treated with RT (HR [95%CI]: 2.5 
[0.8, 7.8]; p=0.11); however, this analysis might not have been adequately powered, given the 
point estimate, as only 35 events were observed.(222) These findings are consistent with 
another comparison of rates of metastatic progression among men diagnosed with 
unfavorable-risk PCa and treated with EBRT+ADT relative to RP.(221) The attenuated effect 
estimate in our study relative to previous studies might be attributable to non-consistency in 
ADT administration, as only 57.9% of men in our study received any neoadjuvant or adjuvant 
ADT whereas ADT use in the aforementioned studies among those treated with EBRT was 
approximately 100%.  
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Substantial variation in oncological outcomes has also been observed with the use of 
combination EBRT+BT relative to EBRT alone. For instance, lower rates of metastatic 
progression have been found among men diagnosed with unfavorable-risk non-metastatic PCa 
and treated with combination EBRT+BT relative to RP (0.27 [0.17, 0.43]). This finding is 
consistent with other reports demonstrating improved PCa-specific survival among 
combination EBRT+BT relative to EBRT alone.(211,212) Only 19 (11.2%) men in our cohort 
received combination EBRT+BT so subgroup comparisons were not feasible. As such, our 
findings likely represent a combination of two different effect estimates for combination 
EBRT+BT and EBRT alone. 
 The rate of salvage therapy post-RP was much higher than that post-RT. Local and 
systemic salvage therapy were administered to approximately 30% of men post-RP, while only 
one man treated with RT received salvage therapy. These observations are consistent with 
previous investigations by Kishan et al who found similar rates of local and systemic salvage 
therapy post-RP,(220) and Markovina et al who found salvage much more common post-RP 
than post-RT.(221) This can, in part, be explained by the increased rates of biochemical-failure 
among men diagnosed with unfavorable-risk non-metastatic PCa who undergo RP relative to 
RT. Administration of salvage therapy is also less likely among men undergoing RT. Since men 
who undergo RT are generally older, with poorer health and lower life expectancies, the 
benefits of salvage therapy are limited, while side effects from it can adversely affect quality of 
life. Moreover, the rate of salvage therapy post-RT might be hampered due to limited 
awareness and availability of modalities such as cryotherapy and high intensity focused ultra-
sound. 
 135 
 The median follow-up time was 13 months shorter in the RT relative to the RP group. 
This might be explained by increased rates of competing events that would increase losses to 
follow-up. To explain, those receiving RT were also approximately 10 years older than those 
receiving RP and likely had increased comorbidities. During later phases of PCa management, 
competing illnesses that decrease life-expectancy may take priority and patients might stop 
attending follow-up appointments for their PCa if it poses less threat to their survival. 
Unfortunately, data from other clinics indicating development of metastasis was not available, 
preventing competing risks analyses. This missing data issue can bias effect estimates either 
through limiting the contribution of event-free follow-up time or limiting the identification 
metastatic progression.  
Other missing data issues involved 17 subjects for clinical tumor stage and 23 subjects 
for percent core positivity, which prevented these observations from contributing to regression 
and post-matching effect estimation. However, due to the limited number of subjects missing 
information on these variables, inferences regarding the distribution of missing data is limited 
and data imputation methods, such as multiple imputation, are unlikely to lead to notably 
different effect estimates or provide additional information.  
 The strengths of our study include the comparison of men treated with RT who were 
also eligible for RP thereby mitigating violations of positivity required for the conduct of 
regression analysis.(183) Moreover, systematic identification of comparable treatment groups 
through propensity score matching and coarsened exact matching has potential to reduce 
reliance on model specification,(138) thereby improving the robustness of confounding control. 
Finally, since men were diagnosed between 2007 and 2012 from two large academic centers, 
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treatment approaches are expected to be more consistent with contemporary treatment 
approaches. 
 The findings of this study are subject to limitations. First, the proportion of men treated 
with RT who received ADT was much lower than other similar investigations. Since ADT has 
been shown to decrease the rate of metastatic progression, the rates observed among men 
treated with RT in our cohort may exceed those achievable through the current standard of 
care, which recommends RT and ADT for men diagnosed with unfavorable-risk PCa.(90) In 
addition, the series of men treated at LHSC may not have been comparable to men treated at 
GGWPC so there is potential for confounding of effect estimates by treatment center. Finally, 
due to data limitations, percent of tumor containing biopsy cores, comorbidities, and 
socioeconomic and demographic characteristics could not be controlled for, potentially biasing 
effect estimates. Based on the risk of bias assessment tool used in the chapter seven, this study 




 The results from our study support findings from previous analyses that more 
contemporary forms of treatment involving RT as an initial strategy may be, at least, 
comparable to those involving initial RP for men diagnosed with unfavorable-risk PCa. 
Furthermore, the decreased use of salvage therapies among men treated with RT relative to RP 
may have benefits with regard to fewer side effects in the long-term management of this 
patient population. Given the aforementioned limitations of this study, the results provided 
here must be interpreted with caution. However, since evidence from RCTs is unlikely to 
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surface within the next decade,(109) the value of observational research holds great value in 




8.0 Integrated Discussion 
  
In this thesis, we developed a systematic approach to developing and evaluating 
matching strategies that improve balance in the multivariable distribution of baseline 
covariates while optimizing data retention. In our analyses, both propensity score matching, 
and coarsened exact matching performed similarly. However, due to the small number of 
covariates, the performance of coarsened exact matching might decrease with larger covariate 
sets, as shown in previous studies.  
One concern with propensity score matching is its limited ability to balance past the 
propensity score matching paradox. A hybrid matching approach, with elements of both 
propensity score matching and coarsened exact matching, could be used to overcome the 
limitations of propensity score, and coarsened exact matching. Specifically, matching on latent 
variables would reduce the number of variables used in coarsened exact matching, while 
providing more granular data than the scalar value of the propensity score from which to 
inform matches to improve balance potential past the propensity score matching paradox. For 
example, a latent variable for risk of extraprostatic extension could be represented by PSA, 
Gleason Grade, clinical tumor stage, and percent of positive biopsy cores. Another latent 
variable for how estimated life expectancy impacts treatment decisions could be modeled using 
comorbidity information and age at diagnosis.  
Moving forward, I am currently working with a PhD candidate in Statistics at the 
University of Waterloo to develop an RStudio package to improve upon the statistical 
sophistication and automatization of the systematic matching algorithm developed in chapter 
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four. This work will provide analysts with an open access to a more user-friendly version of our 
systematic approach to matching and hopefully improve the quality of matching in the realm 
comparative effectiveness research using non-experimental data. We also aim to develop a 
latent variable matching strategy and assess its performance relative to propensity score 
matching and coarsened exact matching, using the approach demonstrated in chapter five.  
The matching methods developed and presented in this thesis (specifically in chapter 
four) were used in chapter seven to compare the rate of metastatic progression between men 
diagnosed with unfavorable-risk non-metastatic prostate cancer who were initially treated with 
radiation therapy or radical prostatectomy. Despite the high-level of sophistication in the 
management of confounding through matching and regression modeling, the risk of bias in this 
study was still deemed to be high. This was the case for each study included in the systematic 
review and meta-analysis performed in chapter six as well. There are two reasons for this. Most 
studies, including that performed in chapter seven, did not involve all observable confounding 
variables. The second reason pertains to the inappropriate use of matching and regression 
strategies. 
The reason for not including all potentially confounding variables could be due to 
limitations in obtaining information on comorbidities, demographic, socioeconomic, 
geographic, diagnostic, treatment, and outcome information. Institutional databases included 
in our systematic review and meta-analysis generally provided sufficient detail on diagnostic, 
treatment, and outcome related information. However, information pertaining to 
comorbidities, geographic location, demographic, and socioeconomic characteristics were 
generally unavailable. On the other hand, national registry databases provided this information, 
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but in turn lacked detailed diagnostic, treatment and/or outcome related information. In our 
case, primary care medical records of patients diagnosed and treated at the GGWPC and LHSC 
were not readily obtainable due to concerns with privacy and confidentiality as well as 
practicality in collating information from paper-based documents and electronic medical 
records that likely used different software platforms. This resulted in inconsistently reported 
and incomplete information on comorbidities, demographic, socioeconomic, and geographic 
location, limiting our ability to effectively control for any potential confounding these variables 
might have introduced.  
A concerted effort to improve the standardization in reporting diagnostic, treatment, 
and clinical follow-up information in detail and that has potential for linkage with medical 
records from primary and tertiary care providers (to provide information on comorbidities) and 
with administrative databases (that have demographic, and socioeconomic information) would 
have great value in the realm of comparative effectiveness research. This has been 
demonstrated, to some extent, with the National Prostate Cancer Register in Sweden, which 
collects detailed screening, diagnostic, risk-stratification, treatment and follow-up information 
and has potential for linkage to other national registries with information on comorbidities, 
demographic, socioeconomic, and geographic location.(223) However, follow-up information 
on margin status post-RP, biochemical progression, and metastatic progression and subsequent 
adjuvant and salvage therapy is still lacking. 
To overcome the inappropriate use of regression techniques used in comparative 
effectiveness research, research ethics boards, grant reviewing bodies, and other organizations 
should ensure that projects meet standards for statistical analyses. Additionally, academic 
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journals, such as the Journal of Urology, should continue to mandate that authors report 
specifics related to their statistical analyses, ensuring standard recommendations are met. This 
approach should be emulated by all journals to motivate the proper use and reporting of 
statistical analyses. An explanation for the subpar use of matching techniques could be due to 
the relatively recent development of any standardized guideline.(140) Further, such guidelines, 
as shown in chapter four, are incomplete in that no set of balance diagnostics are 
recommended to guide the development and evaluation of matching strategies.  
It is my goal that through the publication of the recommended set of balance 
diagnostics presented in chapter three and the proposed systematic approach to developing 
and evaluating propensity score models for matching presented in chapter four, that the 
conduct of propensity score matching might improve in the field of prostate cancer and other 
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Supplementary Tables and Figures 
 
S Table 5.1a Characteristics of PSM strategies for comparison one 
PSM Strategy Caliper Width SD of logit(PS) BT+ADT (n) E+ADT (n) Events (n) 
Unmatched - 433 132 56 
Nearest no caliper 396 132 56 
1 2.0 343 132 52 
2 1.5 321 125 51 
3 1.0 299 122 48 
4 0.8 287 121 47 
5 0.6 274 118 44 
6 0.5 270 117 45 
7 0.4 268 116 45 
8 0.3 264 114 45 
9 0.2 258 112 44 
10 0.1 248 109 41 
11 0.05 234 104 37 
12 0.025 214 104 33 
13 0.01 182 82 30 
14 0.005 139 69 24 
 
S Table 5.1b Characteristics of PSM strategies for comparison two 
PSM Strategy Caliper Width SD of logit(PS) E+ADT (n) EBRT (n) Events (n) 
Unmatched - 579 126 256 
Nearest No caliper 504 126 237 
1 2.0 443 126 210 
2 1.5 405 126 192 
3 1.0 374 126 180 
4 0.8 361 126 175 
5 0.6 352 126 173 
6 0.5 347 126 171 
7 0.4 345 126 170 
8 0.3 343 124 167 
9 0.2 339 121 164 
10 0.1 330 115 156 
11 0.05 303 111 138 
12 0.025 277 105 130 
13 0.01 230 90 109 





S Table 5.2a Coarsening of covariates used in CEM for comparison one 
Variable Coarsening Matching Range Boundaries 
PSA (ng/ml)    
 1 0, 2, 4, 6, 8, 10, 13, 16, 20 
 2 0, 2, 4, 7, 10, 14, 20 
 3 0, 4, 10, 20 
Treatment Year   
 1 Exact 
 2 1997, 2000, 2002, 2004, 2007 
 3 1997, 2002, 2007 
 
 
S Table 5.2b Coarsening of covariates used in CEM for comparison two 
Variable Coarsening Matching Range Boundaries 
PSA (ng/ml)    
 1 0, 2, 4, 6, 8, 10, 13, 16, 20 
 2 0, 2, 4, 7, 10, 14, 20 
 3 0, 4, 10, 20 
Treatment Year   
 1 1995, 1997, 1999, 2001, 2003, 2006 
 2 1995, 1999, 2002, 2006 
 3 1993, 1999, 2006 
EBRT Dose (Gy)   




S Table 5.3a Characteristics of CEM strategies for comparison one 
CEM Strategy RT Year Coarsening PSA Coarsening BT+ADT (n) E+ADT (n) Events (n) 
Unmatched - - 433 132 56 
1 3 3 391 123 50 
2 3 2 371 116 48 
3 3 1 363 109 45 
4 2 3 372 112 41 
5 2 2 353 106 40 
6 2 1 343 100 38 
7 1 3 308 107 35 
8 1 2 276 96 34 
9 1 1 242 90 32 
 
S Table 5.3b Characteristics of CEM strategies for comparison two 






E+ADT (n) EBRT (n) Events (n) 
Unmatched - - - 579 126 256 
1 3 3 1 492 123 227 
2 3 2 1 445 122 209 
3 3 1 1 436 119 203 
4 3 3 1 439 122 211 
5 3 2 1 398 122 194 
6 3 1 1 373 118 180 
7 2 3 1 377 118 176 
8 2 2 1 337 116 160 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































S Figure 5.2a Distribution of baseline ln(PSA) in BT+ADT (blue) and E+ADT (orange) groups for unmatched 






S Figure 5.2b Distribution of RT start year in BT+ADT (blue) and EBRT+ADT (orange) groups for 









































































































































































































































































































































































































































































































































































































































































































































































































S Figure 5.4a Distribution of baseline ln(PSA) in E+ADT (blue) and EBRT (orange) groups for unmatched 






S Figure 5.4b Distribution of RT start year in E+ADT (blue) and EBRT (orange) groups for unmatched 





S Figure 6.1 Forest plot showing subgroup effects for EBRT and EBRT+BT assessing 
the risk of (a) prostate cancer-specific mortality and (b) all-cause mortality following 
radiotherapy and surgery for prostate cancer 
Abbreviations: HR = hazard ratio; CI = confidence interval; RP = radical prostatectomy; RT = radiation therapy; EBRT 
























S Figure 6.2 Forest plot showing subgroup effects for studies conducted among 
younger and older patient groups assessing the risk of (a) prostate cancer-specific 
mortality and (b) all-cause mortality following radiotherapy and surgery for prostate 
cancer 
Abbreviations: HR = hazard ratio; CI = confidence interval; RP = radical prostatectomy; RT = radiation therapy; CSM 




S Table 7.1 Ranges of coarsened variables 
Variable Ranges 
PSA (ng/ml) 0, 20, 100, 300 
 0, 20, 30, 50, 100, 300 
 0, 6, 10, 20, 30, 50, 100, 300 
Gleason Score 6, 8, 10 
 6, 7, 8, 9, 10 
Clinical Tumor Stage 1, 2, 4, 






S Figure 7.1a The average absolute standardized mean difference (SMD) is plotted per 
level of data retention for each matching caliper used in propensity score matching.  




























S Figure 7.1b The number of absolute standardized mean differences (SMD) that 
exceed the threshold of 0.1 is plotted per level of data retention for each matching 
caliper used in propensity score matching.  































S Figure 7.1c The average absolute standardized mean difference (SMD) for the 
proportion of patients in each treatment group occupying each ProCaRS risk-group (i.e., 
high-intermediate, high, and extremely high) is plotted per level of data retention for 
each matching caliper used in propensity score matching.  



























S Figure 7.1d The variance ratio for baseline PSA between treatment groups is plotted 
per level of data retention for each matching caliper used in propensity score matching.  


























S Figure 7.2a The average absolute standardized mean difference (SMD) is plotted per 
level of data retention for each combination of coarsened variables used in coarsened 
exact matching.  

























S Figure 7.2b The number of absolute standardized mean differences (SMD) that 
exceed the threshold of 0.1 is plotted per level of data retention for each combination of 
coarsened variables used in coarsened exact matching.  
























S Figure 7.2c The average absolute standardized mean difference (SMD) for the 
proportion of patients in each treatment group occupying each ProCaRS risk-group is 
plotted per level of data retention for each combination of coarsened variables used in 
coarsened exact matching.  

























S Figure 7.2d The variance ratio for baseline PSA between treatment groups is plotted 
per level of data retention for each combination of coarsened variables used in 
coarsened exact matching.  























Appendix A: Data Extraction Items 
 
a) General study information: 
- Title 
- Authors 
- Publication date 
- Study design 
o Prospective vs retrospective 
- Data source: 
o National-level databases 
o Single-institutional 
o Multi-institutional 
o Range of calendar years of diagnosis and treatment included 
o Geographical location 
 
b) Prostate cancer, treatment and endpoint information: 
- Dates of patient inclusion 
- Follow-up duration 
- Median age in each group 
- Treatment information:  
o Number treated in each group 
o Approach to radiotherapy (e.g., dose, fractions, duration, 3D, IMRT, 
brachytherapy, dose-escalation, proton beam, SBRT, combination, etc.) 
o approach to radical prostatectomy (e.g., open- retropubic or perineal, 
laparoscopic or robotic) 
o use of neoadjuvant or adjuvant hormonal or chemotherapy and duration 
- Adjusted HR for prostate cancer-specific mortality and all-cause mortality 
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Appendix B: Search Strategy 
 
A search strategy was performed by Gabriel Boldt, a clinician librarian, and yielded a total of 
5,487 articles total between PubMed and EMBASE databases before screening. Search 
strategies was completed as follows:  
 
PubMed Strategy: 
(radiotherapy[mh] OR radiation therapy[tw] OR radiotherapy[tw] OR surgery[mh] OR 






(high risk[tw] OR intermediate[tw] OR non-metastatic[tw] OR nonmetastatic[tw] OR 
localised[tw] OR localized[tw] OR locally[tw] OR local[tw]) 
NOT 
review[pt] 




(radiotherapy.mp. or exp radiotherapy/ or radiation therapy.mp. or surgery.mp. or exp surgery/ 
or exp prostatectomy/ or prostatectomy.mp. or surgeries.mp.) 
and  
(prostate tumor/ or prostat*.mp. or exp prostate carcinoma/ or exp prostate cancer/ or exp 
prostate hypertrophy/) 
and 
(surviv*.mp. or exp survival/) 
and 
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(high risk or intermediate or non-metastatic or nonmetastatic or localised or localized or locally 
or local).mp. 




Appendix C: Modified Newcastle-Ottawa Scale for Risk of Bias Assessment 
 
Items having potential to bias the relationship between treatment modality (i.e. radical 




1. Representativeness of the exposed cohort 
a. 1 point for data representing the general population (i.e. in terms of 
socioeconomic and demographic characteristics) 
b. 0 point if data is not representative or indicated (e.g. selected group of users like 
nurses, volunteers, insured, safety-net hospitals, secondary data from other 
clinical population, etc.) 
 
2. Representativeness of the non-exposed cohort 
a. 1 point if drawn from the same community as the exposed cohort 
b. 0 points if drawn from a different source or not specified 
 
3. Ascertainment of exposure 
a. 1 point if obtained from a secure record (e.g. surgical records) or self-report 
b. 0 points if no description 
 
4. Demonstration that outcome of interest was not present at the start 
a. 1 point if yes 




5. Comparability of treatment groups after matching (if applicable) or accounted for in 
multivariable analysis. Maximum of 4 points awarded if the following factors are 
controlled for or not significantly different after matching as indicated by a standardized 




iv. Comorbidity status 
v. Age 
vi. ≥1 of year of diagnosis or treatment 
vii. ≥1 demographic characteristic (education, income, rural/urban) 
viii. Study center (if multiple) 
b. 0.5 point deducted for each variable not included in the model, unless tested 





6. Ascertainment of outcome 
a. 1 point if record linkage or blind assessment 
b. 0 points if assessment is not blinded or not reported 
 
7. Adequacy of follow-up of cohorts  
a. 1 point if no subjects lost to follow up or those lost are unlikely to introduce bias 
(i.e. number lost ≤20% or description of those lost suggested no different from 
those followed) 
b. 0 points if follow up rate <80% and no description of those lost or if no 
statement was made 
 
8. Was follow-up long enough for outcomes to occur? 
a. 1 point if median follow-up was ≥10 years, as 10-year cancer specific survival is 





Thresholds for converting to low, moderate and high risks of bias: 
 
Low risk of bias: ≥3 points in selection domain AND 4 points in comparability domain AND ≥2 
points in outcome domain 
 
Moderate risk of bias: 2 points in selection domain AND 4 points in comparability domain AND 
≥2 points in outcome domain 
 
High risk of bias: ≤1 point in selection domain OR ≤3 points in comparability domain OR ≤1 
point in outcome domain 
 
This scoring system is adapted from the Newcastle Ottawa Scale. We gave more weight to Item 
5 as these confounding variables have demonstrated substantial impact on the comparison 
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